[COMPANY_001] Confidential Page 2
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Table of contents
Table of contents ................................................................................................................. [ADDRESS_1048625] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 11
Amendment 3 ........................................................................................................................... 12
Protocol summary .............................................................................................................. 15
1Introduction ....................................................................................................................... 18
1.1 Background ............................................................................................................ 18
1.2 Purpose .................................................................................................................. 34
2Study  objectives and endpoints ......................................................................................... 34
2.1 Objectives and related endpoints ........................................................................... 34
3Investigational plan ........................................................................................................... 36
3.1 Study  design ........................................................................................................... 36
3.2 Rationale for stud y design ..................................................................................... 38
3.3
Rationale for dose/regimen, route of administration and duration of treatment ....38
3.4 Rationale for choice of compar ator....................................................................... 39
3.5 Purpose and timing of interim anal yses/design adaptations .................................. 40
3.6 Risks and benefits .................................................................................................. 40
4Population .......................................................................................................................... 42
4.1 Inclusion criteria .................................................................................................... 42
4.2 Exclusion criteria ................................................................................................... 42
5Treatment ........................................................................................................................... 45
5.1 Study  treatment ...................................................................................................... 45
5.1.1 Investigational and control drugs .......................................................... 45
5.1.2 Additional treatment .............................................................................. 46
5.2 Treatment arms ...................................................................................................... 46
5.3
Treatment assignment and randomization............................................................. 46
5.4 Treatment blinding ................................................................................................. 47
5.5 Treating the patient ................................................................................................ 47
5.5.1
Patient numbering ................................................................................. 47
5.5.2 Dispensing the stud y drug ..................................................................... 48
5.5.3 Handling of study  and additional treatment .......................................... 48
5.5.4 Instructions for prescribing and taking stud y treatmen t
........................ 49
5.5.5 Permitted dose adjustments and interruptions of study  treatment ........ 50

[COMPANY_001] Confidential Page 3
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
5.5.[ADDRESS_1048626] -study  treatment .......................................... 53
5.6.2 Discontinuation of study  treatment ....................................................... 54
5.6.3 Withdrawal of informed consent ........................................................... 55
5.6.4 Loss to follow -
up .................................................................................. 55
5.6.5 Early study termination by [CONTACT_456] ................................................. 55
6
Visit schedule and assessments ......................................................................................... 56
6.1 Information to be collected on screening failures .................................................. 65
6.1.1 Pre-screening ......................................................................................... 65
6.2 Patient demographics/other baseline characteristics ............................................. 66
6.2.1 Demographic Information ..................................................................... 66
6.2.2 Medical history
...................................................................................... 66
6.2.3 Alcohol history  and assessments ................................ ........................... 66
6.2.4 Smoking history .................................................................................... 66
6.2.5 Prior and concomitant me dications ....................................................... 66
6.2.6
Liver evaluation .................................................................................... 66
6.2.7 Other baseline characteristics ................................................................ 67
6.2.8
Screening visit 2 – additional assessments ............................................ 68
6.3 Treatment exposure and compliance ..................................................................... 68
6.4 Efficacy .................................................................................................................. 68
68
6.4.2 Liver tests .............................................................................................. 69
6.4.3 Coagulation tests ................................................................................... 69
69
69
70
70
70
6.4.9 Liver biopsy .......................................................................................... 70
6.4.10 Appropriateness of efficacy  assessments .............................................. 71
6.5 Safety ..................................................................................................................... 71
6.5.1 Physical examination ............................................................................ 71

[COMPANY_001] Confidential Page 4
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.5.2 Vital signs .............................................................................................. 72
72
6.5.4 Laboratory  evaluations .......................................................................... 72
6.5.5 Electrocardiogram (ECG) ..................................................................... 73
6.5.6 Pregnancy  and assessments of fertility ................................................. 74
6.5.7 Appropriateness of safety  measurements .............................................. 74
6.6 Other assessments .................................................................................................. 74
6.6.1 Clinical Outcome Assessments ............................................................. 75
6.6.2 Resource utilization ............................................................................... 77
77
78
78
7Safety  monitoring .............................................................................................................. 78
7.1 Adverse events ....................................................................................................... 78
7.2 Serious adverse events ........................................................................................... 80
7.2.1 Definition of SAE ................................................................................. 80
7.2.2 SAE reporting
........................................................................................ 81
7.3 Liver safety  monitoring ......................................................................................... 82
7.4 Renal safet y monitoring ......................................................................................... 83
7.5 Reporting of stud y treatment errors including misuse/abuse ................................ 83
7.6 Pregnancy  reporting ............................................................................................... 84
8Data review and database management ............................................................................. 84
8.1 Site monitoring ...................................................................................................... 84
8.2
Data collection....................................................................................................... 85
8.3 Database management and quality  control ................................ ............................ 85
8.4 Data Monitoring Committee .................................................................................. 86
8.5 Adjudication Committee ........................................................................................ 86
9Data analy sis...................................................................................................................... 87
9.1 Analy sis sets .......................................................................................................... 87
9.2
Patient demographics and other baseline characteristics....................................... 87
9.3 Treatments ............................................................................................................. 87
9.4 Analy sis of the primary  variable(s) ....................................................................... 88
9.4.1 Primary  Variable(s) ............................................................................... 88
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 88
9.4.3 Handling of missing values/censo ring/discontinuations ....................... 88
9.4.4 Sensitivity  analy ses............................................................................... 89

[COMPANY_001] Confidential Page 7
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
List of abbreviation s
A14 Inducible cytokine Alpha -[ADDRESS_1048627] Research Organization
CSR Clinical Study Report
CV Central Vein

[COMPANY_001] Confidential Page 8
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
CVC Cenicriviroc Mes ylate
CYP3A4 Cytochrome P450 3A4
CYP7A1 Cytochrome P450 7A1
CYP2C8 Cytochrome P450 2C8
DBP Diastolic Blood Pressure
DDI Drug Drug Interaction
DMC Data Monitoring Committee
EC50
eCRFHalf Maximal Effect Concentration
electronic Case Report Form
ECG Electrocardiogram
EDC Electronic Data Capture
eGFR Estimated Glomerular Filtration Rate
EMA European Medicines Agency
EOT End of treatment
EOS End of study
eSource Electronic Source
FAS Full analy sis set
FXR Farnesoid X Nuclear Receptor
GCP Good Clinical Practice
GGT Gamma -glutam yl Transferase
GLP Good Laboratory Practice
GLP-1 Glucagon -like Peptide -1
HA Hyaluronic acid
Hb Hemoglobin
HbA1c Glycated hemoglobin
HBcAb Hepatitis B Core Antibody
HBsAg Hepatitis B Surface Antigen
HCC Hepatocellular Carcinoma
HCV Hepatitis C Virus
hCG Human Chorionic Gonadotropin
HCVAb Hepatitis C virus antibody
HIV Human Immunodeficiency Virus
IB Investigator’s Brochure
ICF Informed Consent Form

[COMPANY_001] Confidential Page 9
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
ICH International Council for Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for H uman Use
ID Identification
IEC Independent Ethics Committee
IN Investigator Notification
INR International Normalized Ratio
IQR Interquartile range
IRB Institutional Review Board
IRT Interactive Response Technology
ITT Intent -to-treat
IUD Intrauterine device
IUS Intrauterine system
LC-MS/MS Liquid chromatography coupled to tandem mass spectrometry
LLOQ Lower limit of qualification
LT Liver test
MCV Mean Corpuscular Volume
MDRD Modification of Diet in Renal Disease
MedDRA Medical dictionary for regulatory activities 
MI Myocardial Infarction
  
 
 
NAFLD Non-alcoholic Fatty Liver Disease
NASH Nonalcoholic Steatohepatitis
NSAIDs Nonsteroidal Anti-inflammatory Drugs
OCA Obeticholic acid
PBC Primary Biliary Cholangitis
PCR Protein -creatinine ratio

[COMPANY_001] Confidential Page 10
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
PRO Patient Reported Outcomes
PSC Primary Sclerosing Cholangitis
PT Prothrombin Time/Portal Triad
PUFA Polyunsaturated Fatty Acids 
QM Quality Management
QTcF Corrected QT interval (Fridericia method)
RAN Randomized set
RBC Red Blood Cell
RNA Ribonucleic Acid
SAF Safety set
SBP Systolic Blood Pressure
sCD163 Soluble Cluster of differentiation [ADDRESS_1048628] Upper Limit Normal
WBC White Blood Cells
WHO World Health Organization 
WoC Withdrawal of Study Consent
yGT y-Glutam yltranspeptidase

[COMPANY_001] Confidential Page 11
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Glossary  of terms
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve blinding 
of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 100 mg 
once a day, 75 mg b.i.d).
Electronic Data Capture 
(EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as W eb-based applications, 
interactive voice response systems and clinical laboratory interfaces.
EDC includes the use of Electronic Case Report Forms (eCRFs) wh ich are 
used to capture data transcribed from paper source forms used at the point of 
care.
Enrollment Point/time of patient entry into the study at which informed consent must be 
obtained (e.g. prior to starting any of the procedures described in the 
protocol).
Investigational drug The drug whose properties are being tested in the study; this definition is 
consistent with US C ode of Federal Regulations (CFR) 21 Section 312.3 and 
is synonymous with “investigational new drug” or “investigational medicinal 
product.”
Medication pack number A unique identifier on the label of each investigational drug package .
Part A single component of a study which contains d ifferent objectives or 
populations within that single study. Common parts within a study are: a single 
dose part and a multiple dose part, or a part in patients/subjects with 
established disease and in those with newly -diagnosed disease.
Patient/subject Identification 
(ID)A unique number assigned to each patient upon signing the informed consent .
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study phases and w ill 
be used in clinical trial database setup and eventually in analysis .
Personal Data Subject information collected by [CONTACT_221963]. This data includes subject identifier 
information, study information and biological samples.
Randomization number A unique identifier assigned to each randomized patient, corresponding to a 
specific trea tment arm assignment.
Source Data/Document Source data refers to the initial record, document, or primary location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource.
Study drug/ treatment Any single drug or combination of drugs administered to the patient as part of 
the required study procedures; includes investigational drug (s), 
placebo/comparator active drug run -ins or background therapy .
Study Treatment 
Discontinuation (TD)When the patient permanently stops taking study treatment prior to the defined 
study treatment completion date .
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the study .
Withdrawal of study consent 
(WoC)Withdrawal of consent from the study occurs only when a subject does not 
want to participate in the study any longer, and does not allow any further 
collection of personal data .

[COMPANY_001] Confidential Page 12
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Amendment [ADDRESS_1048629] visit schedule and assessments as outlined 
in Table 6 -1should resume as soon as patients are able to visit study  sites and undergo all e nd 
of treatment assessments
At the time of amendment (V03) release, enrollment is completed with 193 patients randomized. 
Changes to the protocol
This amendment provides the option to extend the study  treatment for patients who are unable 
to come to site for the week 48 visit as scheduled due to COVID -19 pandemic restrictions.
The c hanges to specific sections of the protocol are as below:
Section 3.6: Updated to clarify  the possible benefits and risks of longer study  treatment 
Section 5.5.2: updated to include the stepwise approach to extend study  treatment for 
patients who are unable to come to the study  site for their 
Week-48, End of treatment 
(EOT) visit as scheduled per study  protocol due to COVI D-19 pandemic related 
restrictions
Section 6 and table 6.1: updated to include remote consultation for patients who are 
unable to come to the study site for their study  visits (except week
-48, End of treatment 
visit) as scheduled per study  protocol due to COVID -[ADDRESS_1048630] and study 
treatment extension. 
Section 9.5.1: updated to clarify  analysis plan for the delay ed Week 48, End of 
Treatment (EOT) visits due to COVID -19 pandemic related restrictions
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities. This amendment is 
required to ensure trial continu ity due to COVID -19 pandemic and related measures , therefore 
it will be implemented prior to Health Authority  and IRB/IEC approval.
The 
changes herei n affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 

[COMPANY_001] Confidential Page 15
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Protocol summary
Protocol number CLJC242A2201J
Full Title A randomized, double -blind, multicenter study to assess the safety, 
tolerability, and efficacy of a combination treatment of tropi[INVESTIGATOR_421736] 
(LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic 
steatohepatitis (NA SH) and liver fibrosis (TANDEM )
Brief title Study of safety , tolerability, and efficacy  of a combination treatment of 
tropi[INVESTIGATOR_765017] (NASH) and liver fibrosis
Sponsor and Clinical 
Phase[COMPANY_001] 
Phase 2 b
Investigation type Drug
Study type Interventional 
Purpose and rationale The purpose of this study is to assess the safety, tolerability, efficacy  
 of two regimens of tropi[INVESTIGATOR_765018] (CVC) 
(further described as tropi[INVESTIGATOR_421736] +CVC) compared to monotherapi[INVESTIGATOR_765019]. 
Primary Objective(s) The primary  objective of this study is t o evaluate the safety and 
tolerability of tropi[INVESTIGATOR_421736] + CVC in patients with NASH withfibrosis stage 
F2/F3by [CONTACT_12902], vital signs and laborator y values 
during 48 weeks of treatment as compared to monotherapy with each of 
tropi[INVESTIGATOR_765020] +CVC in patients with NASH withfibrosis stage F2/F3 as 
assess ed by [CONTACT_765083] 48 weeks of treatm ent 
compared to monotherapi[INVESTIGATOR_014] (tropi[INVESTIGATOR_765021]) compared to baseline 
biopsy .
Study design This study is arandomized, double- blind, multicenter study to evaluate 
the safety and tolerability of tropi[INVESTIGATOR_421736] +CVC as compared to 
monotherapy with each of tropi[INVESTIGATOR_765021] .
Population Adult male and female patients with histologic evidence o f NASH with 
stage 2 or 3 fibrosis based on centrally -read liver biopsy .
The study will include a total of approximately 200patients.
Key Inclusion criteria Written informed consent must be obtained before any assessment is 
performed.
Male and female patients 18 years or older (at the time of the 
screening visit). Patients must weigh at least 50 kg (110 lb) and no 
more than 200 kg (440 lb) to participate in the study.
Adequate liver biopsy sample for evaluation by a central reader.
Presence of NASH as demonstrated by [CONTACT_765084] - NASH with fibrosis stage F2/F3 , demonstrated on liver 
biopsy during the screening period. Alternatively, a historical biopsy 
can be used if performed within 6 months prior to s creening, if:
the patient has been receiving any of the therapi[INVESTIGATOR_180568] 
5-4, the dose must have been stable (since 1 month before the 
biopsy up to and including screening) ,
the patient’s weight has been stable (maximum weight loss of 
10% since bi opsy up to and including screening).

[COMPANY_001] Confidential Page 17
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
There is a single secondary objective in this study which is to 
characterize the efficacy of tropi[INVESTIGATOR_421736] + CVC as assessed by [CONTACT_765085] 48 weeks of treatment compared to monotherapi[INVESTIGATOR_014] 
(tropi[INVESTIGATOR_765021]) relative to baseline biops y.There are two estimands 
that will be used to evaluate this objective. 
The first estimand is the difference on the proportion of patients on the 
different tropi[INVESTIGATOR_421736] + CVC regimens who achieve at least a one point 
improvement in fibrosis a t We ek 48 com pared to tropi[INVESTIGATOR_765022].
The second estimand is the difference in the proportion of patients on the 
different tropi[INVESTIGATOR_421736] + CVC regimens who achieve resolution of 
steatohepatitis at W eek 48 relative to baseline compared to tropi[INVESTIGATOR_765023] .
Differences between tropi[INVESTIGATOR_421736] + CVC combination therapy and 
monotherapy with tropi[INVESTIGATOR_765024] 
(response rates) will be evaluated using a Cochran -Mantel -Haenszel test 
controlli ng for baseline fibrosis stage (F2/F3). The estimand will be 
evaluated in the FAS population .
Key words Tropi[INVESTIGATOR_421736], LJN452, cenicriviroc, CVC, non-alcoholic steatohepatitis, 
NASH, phase 2, liver biopsy, randomized

[COMPANY_001] Confidential Page 18
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
1 Introduction
1.1 Background
Nonalcoholic Fatty  Liver Disease and Nonalcoholic Steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease 
in developed countries with a global prevalence of 25% (Younossi ZM2011 ,Cohen JC 2011 ,
Younossi et al 2016). NAFLD is often a “silent” liver disease and usually  associated with 
obesity , Type-2 diabetes mellitus (T2DM), dyslipi[INVESTIGATOR_035], hypertension and metabolic syndrome.  
Although most patients with NAFLD have a benign course, a subset of these patients may have 
the more severe and progressive form of NAFL D called nonalcoholic steatohepatitis (NASH), 
which is characterized by [CONTACT_765086]. 
Figure 1-1 Schematic progression of NAFLD/ NASH
The disease spectrum of nonalcoholic fatty liver disease. (A) Schematic of progression of NAFLD. The 
accumulation of Trigly
cerides (TG)within lipid droplets in hepatocytes causes steatosis. Steatosis 
associated with inflammation, cell death, and fibrosis is referred to as NASH, which can progress to 

[COMPANY_001] Confidential Page 19
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
cirrhosis. Individuals with cirrhosis have an increased risk of hepatocellular carcinoma (HCC). (B) 
Histological sections illustrating normal liver, steatosis, NASH, and cirrhosis. Collagen fibers are 
stained blue with Masson’s trichrome stain. The portal triad (PT), which consists of the hepatic artery, 
portal vein, and bile duct, and the cen tral vein (CV) are shown (Figure from Cohen JC 2011 ).
The projected estimate of NASH with advanced fibrosis is approximately  4.1 million adults in 
the US. (Kabban y MN 2017) .Estimates vary due to the diagnostic modality  used, study 
heterogeneity , but also the region of the world studied. Among NAFLD patients, NASH 
estimates are 29% -59% in North America.  I n the overall global population, NASH prevalence 
is 3.8% (3-6.45%) (Foster et 
al 2012, Younossi et al 2016) .Patients with NASH can progress 
to cirrhosis, liver 
decompensation, hepatocellular carcinoma (HCC), need for a liver 
transplantation, and are at increased risk of death from liver disease. The incidence of advanced 
liver disease, liver failure and HCC related to NAFLD/NASH are increasing dramatically  and 
NASH is projected to become the most common indication for liver transplantation (Beste LA
2015, Wong 2015, Neuschwander and Tetri B 2003 ) . NASH is the cause of progressive fibrosis 
in the patients with NAFLD. Fibrosis is the most important histological feature associated with 
all-cause mortality  (e.g. 
cardiovascular disease) and liver complications in NASH (Angulo 2015, 
Ekstedt 
2006) . Despi[INVESTIGATOR_765025], liver biopsy is still the gold 
standard for diagnosing NASH and assessing the stage of fibrosi
s in patients with NAFL D. Of 
note, rapid progressors may proceed to develop cirrhosis in only a 10-year perio d (Singh S 
2015). Reducing liver fibrosis is expected to improve the long-term clinical outcomes of 
patients with NASH 
(Ratziu V 2015 ).
There are no 
globall y approved treatments for NASH. Several studies have been conducted with 
Vitamin E and thiazolidinediones, but no long-term benefits have been demonstrated. There are 
potential new therapi[INVESTIGATOR_765026], currently  in phase II or III trials, but the reported 
efficacy  from the available studies are still lacking substantial benefit . The significant global 
burden of NASH, the currentl y available study  results especiall y when considered with 
multifactorial etiology  of NAFLD/NASH suggests that combinat ion therapy  of different 
mechanisms of actions will bea more effective therap y for NASH patients. 
Farnesoid X receptor: tropi[INVESTIGATOR_765027], farnesoid X receptor (FXR), is a nuclear receptor expressed in liver,
intestine, and kidney . FXR acts as a sensor of elevated bile acids and initiates homeostatic
responses to control bile acid levels and modulate other metabolic processes such as 
gluconeogenesis and lipogenesis (Figure 1-1) (Pattni et al 2012 , Walters et al 2015 ). In the liver, 
FXR agonism modulates bile acid synthesis and detoxify ing metabolism. FXR agonist increases 
expression of genes involved in canalicular and basolateral bile acid efflux and bile acid 
detoxify ing enzymes while inhibiting basolateral bile acid uptake by [CONTACT_765087] (Calkin and Tontonoz 2012 ). FXR activation represses bile acid synthesis in 
the liver through induction of Small Heterodimer Partner (SHP), which is a negativ
e regulator 
of CYP7A1, the rate-limiting enzy me of the neutral bile acid biosy nthetic pathway  (Goodwin 
et al 2000). Furthermore, FXR agonists increase excretion of bile acids through the kidney, 
increase bile acid binding protei
ns in the ileum and stimulate FGF15 (in rodents) or FGF19 (in 
humans) expression (a key regulator of bile acid metabolism).

[COMPANY_001] Confidential Page 23
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Part 1 of the CLJN452 X2201 study  in PBC patients is ongoing. No safety  concerns were 
identified with doses ranging from 30 to 90 µg orally  once dail y for 4 weeks.
In summary , in clinical studies tropi[INVESTIGATOR_765028], with doses currentl y
being tested up to 200 μg orally  in the ongoing phase 2 NASH program .
C
-C chemokine receptor type 2 and type 5 inhibitor: c enicriviroc
Cenicriviroc mesylate (CVC) is an oral, dual antagonist of C-C motif chemokine receptor types 
2 and 5 currently  in clinical development for the treatment of liver fibrosis in adult patients with 
NASH. The Investigator ’s Brochure (CVC IB) provides a detailed review of the pre-clinical 
and clinical information on CVC available to date.
Human pharmacokinetic and pharmacod ynamic as well as safet y and tolerability  data are 
further described in the CVC I B. Briefl y, CVC has demonstrated antifibrotic activity  in animal 
models of liver and renal fibrosis ( Lefebvre et 
al 2016). Preclinical (Lefebvre et al 2016,
Puengel et al 2016 ,Tacke et al 2015 ,Mossanen et al 2016 )and clinical evidence (Friedman et 
al 2017, Lefebvre et al 2016, Thompson et al 2016) support its anti-inflammatory  and 
antifibrotic properties, which are mediated by C-C motif chemokine receptor types 2 and 5 
blockade. 
The mechanism of action of CVC, as an anti -inflammatory  and anti
-fibrotic agent, supports its 
use in liver diseases, such as liver fibrosis associated with NASH. CVC treatment decreases the 
recruitment and migration of CCR2 -expressing monocytes to the site of liver injury, mainl y via 
CCR2 antagonism, thereby  [CONTACT_765088] -inflammatory , monocy te-derived 
macrophages into the liver (Krenkel O 2017). In addition, CCR5 antagonism by [CONTACT_765089], activation, and prolifer ation of collagen -producing activated 
hepatic stellate cells and my ofibroblasts, therefore reducing fibrogenesis
.
Assessment of cenicriviroc in non- clinical s tudies
In vitro data with CVC have demonstrated that it blocks the binding of C-C motif chemokine 
ligand 2 (CCL 2; also known as monocy te chemotactic protein 1 [MCP -1]) to CCR2, and also 
blocks the binding of CCR5 ligands, CCL 3 (also known as macrophage inflammatory  protein 
[MIP]-1, CCL 4 (also known as MIP-1 and CCL 5 (also known as regulated on activa tion 
normal T -cell expressed and secreted [RANTES]), to CCR5. Ex vivo experiments showed that 
nanomolar concentrations of CVC achieved 98% receptor occupancy  of CCR2 on human 
monocy tes and ~90% receptor occupancy  for CCR5 on human CD4+ and CD8+ T-cells. 
Additionally , CVC was an efficient inhibitor of monocy te and human lymphocy te (primaril y 
T-cells) migration in vitro. CVC’s anti-inflammatory and antifibrotic effects have been 
evaluated in a range of nonclinical models of inflammation and fibrosis, and has demonstrated 
activity  in multiple animal fibrosis models.
The effects of CVC on the central nervous, cardiovascular, and respi[INVESTIGATOR_765029] a core battery  of safety  pharmacology studies. CVC at oral doses up to 1600 mg/kg 
had no effects on the general physical condition or behavior of rats. CVC had no significant  
effects  on  blood  pressure,  heart  rate,  body  temperature,  or  electrocardiogram (ECG) 
parameters (including PR interval, QRS duration, QT interval, and corrected QT interv
al) at 

[COMPANY_001] Confidential Page 24
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
oral doses up to 2000 mg/kg in cynomolgus and no effects on the respi[INVESTIGATOR_697], tidal volume, 
minute volume, or enhanced pause (Penh) up to [ADDRESS_1048631] the 
liver at or near clinical exposures. L iver findings were present in only  1 of 3 species and when 
present, a high safet y margin was apparent (>27 -fold). CVC was not genotoxic, and did not 
adversel y affect fertility  or embry ofetal development ( refer to CVC IB for further details).
Assessment ofcenicriviroc inclinical studies
Overall, asofJanuar y [ADDRESS_1048632] beenexposed toCVC in 
completed andongoing clinical studies (January 2018 Development Safet y Update Report 
cutoff). CVC doses ranged from 25 m g to900 mgacross allCVC studies. There was no 
apparen t dos
e-or exposur e-relationship for safe ty.
Overall, CVC was generally well tolerated in the Phase 1 studies evaluating single 
doses of CVC up to 900 mg and at multiple daily doses of up to 900 mg for ≥7 days.
In participants with mild to moderate hepatic impairment, CVC 150 mg QD for 14 
days was general ly well tolerated regardless of level of hepatic impairment, and no 
safety concerns were identified in this population.
In the Phase [ADDRESS_1048633] adverse events (AEs) were mild or moderate in severi ty.
The most commonly observed AEs (≥ 2%) with CVC in singl e-dose studies were 
headache, nasophar yngitis, all abdominal pain, nausea, vomiting, diarrhea, contact 
[CONTACT_8748], andsomnolence. The most commonly observed AEs (≥ 2%) with CVC in 
multiple- dose studies were headache, and constipation.
In the CENTAUR Phase 2b studyin adult participants with NASH wit h liver fibrosis, 
CVC appears to be safe with no notable differences observed compared to previous 
clinical studies in incidence of treatment -emergent AEs and laboratory abnormalities, 
including liver transaminase elevations, which were general lysimilar between 
treatment group s. Safety findings in CENTAUR were consistent with that of the 
extensive clinical experience with CVC, including the Phase 2 HIV studies.
Study 652-2-203 (CENTAUR) isa 2-yearplacebo -controlled Phase 2bstudy in289 adult 
participants with liver fibrosis and NASH. Enrollment completed in June
[ADDRESS_1048634] 2017. In CENATUR ,theYear 1primar y endpoint 
ofNAFL DActivity  Score (NAS) improvement by [CONTACT_107457] 2points (and noworsening of 
fibrosis) intheintent -to-treat (ITT )population andthekey secondar y endpoint ofresolution 
of steatohepatitis (and noworsening of fibrosis) was achieved inasimilar proportion of 
subjects onCVC (N = 145)andplaceb o (N = 144)(16% vs 19%, p = 0.52and 8% vs 6%,p
=0.49, respective
ly).However, thefibrosis endpoint (i.e., improvement infibrosis by [CONTACT_107457]
1 stage and noworsening ofsteatohepatitis) was met intwice as many  subjects onCVC 
than placebo in theITTpopulatio n (20 % vs 10%; p = 0.02) . At Year 1, a higher proportion of 
participants intheCVC group(29%) compared with thecombined placebo group(19%) had 
an improvement of at least 1 stage at Year 1 per the NASH CRN stagin g system .Similarl y,a 
higher proportion ofparticipants in the CVC group (35%) compared with the combined 

[COMPANY_001] Confidential Page 25
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
placebo group (22%) hadan improvement of atleast 1stage atYear 1 pertheIshak fibrosis 
staging system. Treatment benefits were greater inthose with highe rdisease activi ty and 
fibrosis stage at baseline. Biomarke rs of systemic inflammation were reduced with CVC .In 
summar y,CVC showed aclinically  meaningful antifibrotic benefit and anti-inflammatory  
activit y in NASH patients with liver fibrosis.
Todetermine thedurability  ofhistological improvement achieved after 1 year of treatment, 
improvement in fibrosis by ≥ 1stage wasassessed insubjects with available biopsy  results at
all3 timepoints (baseline, Year 1, andYear 2). Results from this analysisshowed that the 
proportion of subjects in the CVC group who achieved improvement in fibrosis by≥ 1 stage 
attheendof Year 1 andmaintained thisbenefit atYear 2wastwice theproportion of subjects
intheplacebo group (60% versus 30%, respectivel y).Thedurable antifibrotic effect of CVC
wasalsomore apparent inthesubgroup ofsubjects with Stag e 3fibrosis atbaseline, forwhich
theantifibrotic benefit atYear 2was maintained in86% of subjects intheCVC group 
versus 60% in the placebo group. Furthermore, in the subgroup of subjects with f ibrosis Stage 
2or 3atbaseline, a highe r proportion of subjects receiving CVC achieved a ≥ 2-stage 
improvement infibrosis (and noworsening o fsteatohepatitis) at Year 2 relative tosubjects 
recei ving placebo (9.3% in the CVC group versus 2.7% in the placebo group, from baseli ne to 
Year2).When only subjects with Stage 3fibrosis atbaseline were included intheanalysis,
14.0% of subjects receiving CVC versus 4.2% of subjects receiving placebo for2 ye ars 
achieved a ≥ 2-stage improvement infibrosis (and noworsening of steatohepatitis) at Year 2. 
CVC had a generall ycomparable safety and tolerability profile to placebo over [ADDRESS_1048635] 
of CVC treatment observed in the Year 1 primary  anal ysis (Ratziu et al 2018 ).
Given that severi ty offibrosis stage has been shown
tobetheonly histological feature 
independent ly associated with clinical outcomes over thelong term, these results provide 
additiona levidenc e ofthepotentia l ofCVC as a safeandefficaciou spharma cologic treatment 
forliver fibrosis in adults with NASH.
In CENTAUR, thesafet y profile ofCVC(150 mg QD) wascomparable to thatin participants
treated with placebo andwaswell tolerated over 2 years.Thetypes, severity, and frequency 
ofTEAEs reported after 2years ofCVC treatment wasconsistent with those reported after 1
year of treatment. Theoverall incidence ofTEAEs during thestudy was similar  across  the  
treatment  groups  
(≥ 95.0%  of  participants  in each  group).  No deaths occurred during the
study.Thefrequency  and ty pesofTEAEs reported were comparable between treatment groups 
during Year 1 and Year 2.
The frequency of treatment -related events reported after 2 years of CVC treatment 
was comparable to that reported after 1 year of treatment (41.7% vs 42.1%).
The most frequent ly reported dru g-related TEAEs of at least Grade 2 severity through
1 year of treatment were fatigue (2.8%) and diarrhea (2.1%) in the CVC arm 
and headache (3.5%) in the placebo arms.
The most frequent ly reported study drug-related TEAEs of at least Grade 2 severi ty 
through 2 years of treatment were fatigue (5.0%) in the CVC/CVC group, headache

[COMPANY_001] Confidential Page 26
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
in the placebo/CVC group (6.6%), and ALT increased (3.3%) in the placebo/placebo 
group.
For participants who crossed- over from placebo and received CVC for 1 year, the 
frequen cy of TEAEs reported (44.3%) was similar to that reported in participants who 
received 1year CVC during Treatment Period 1 of the study  (41.7%). A smaller 
number of participants experienced TEAEs that resulted in discontinuation of study
drug.
After 2 years of CVC treatment, the number of participants who discontinued the study 
due to a TEAE was greater than that reported for participants treated with 2 years of 
placebo (4.1% vs 0), but was comparable to that reported after 1 year of treatment (6.3%).
Theonly AE leading to discontinuation, regardless of causali ty, reported in at least 
2 participants in the CVC/CVC group was ALT increased (3 participants, 2.5%); 
all were Grade 3 severit y
.
Although the number of participants who experienced serious adverse events (SAEs) 
increased after 2 years of CVC treatment compared to placebo (18.2% vs 11.8%), 
almost all were considered not-related to study drug and did not lead to study
discontinuation.
Only 1 participant experienced a study drug-related event (Grade 3 heartarrh y thmia ),and 
only 1 event led to discontinuation (Grade 3 congestive heart failure considered not 
related to studymedication).
With the exception of treatment -emergent Grade 3 and 4 amyl ase elevations and Grade 
4 lipase elevations observed more frequentl yin the CVC arms versus the placebo arm 
(3.3% versus 1.7%, 2.2% versus 0.0%, and 21.1% versus 16.7%, respectivel y), the 
incidence of treatment -emergent Grade 3 or 4 laboratory results were generall ysimilar
between the CVC arms and the placebo arm
   No meaningful changes in vital signs or anthropometric parameters were observed.
Overall, the proportion of participants with confirmed liver transaminase elevations that 
met protocol -defined biochemical criteria for suspected drug-induced liver injury was 
9.7% in the CVC group and 7.6% in the placebo group during the first year of treatment. 
The frequency  did not increase in CVC-treated participants in Arm A after an additional 
year of treatment with CVC. No cases of H y’s law were ob served in the s tudy. Among 
the participants who met the criterion for suspected drug induced liver injury , 2 
hepatobiliary adverse events of autoimmune hepatitis were reported during Year 1 (1 
participant in the CVC Arm A and 1 participant in the placebo Arm C). These 
participants did not continue onto treatment during Year 2. In addition, a case of possible 
autoimmune hepatitis was observed upon liver biopsy ([ADDRESS_1048636] in CVC Arm A, event 
not reported as an AE or SAE by [CONTACT_093]). No cases of autoimmunehepatitis 
were observed during Year 2 of the study .
   There have been no deaths related to CVC treatment.
Based on the results of CENTAUR, the Phase 3 AURORA study was initiated in April 2017 to 
study  the antifibrotic benefit of CVC as compared with placebo in adults with NASH and Stage 
2 or 3 
fibrosis. CVC is currently  also in Phase 2 development in subjects with prima ry sclerosing 
cholangitis (PSC) . 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
In over 1000 subjects treated, including those with NASH and liver fibrosis, HIV-1 infection, 
and cirrhotics with hepatic impairment, CVC demonstrated good safety  and tolerability
(Abdelmalek M et al 2017, CVC IB) , supporting evaluation in combination therapy  with 
tropi[INVESTIGATOR_765030].  
This study  is the first study  with a combination of tropi[INVESTIGATOR_765031] 48 weeks .
Tropi[INVESTIGATOR_765018] (combination) pre-clinical data
A preclinical animal study  investigating the potential additive effects of CVC and tropi[INVESTIGATOR_765032], shows that combination therapy  of tropi[INVESTIGATOR_765033], ballooning, and inflammation as measured by [CONTACT_765090]. vehicle 
when compared to either agent as monotherap y (Laffitte B, AASLD [ADDRESS_1048637] # P-2052). 
The combination of tropi[INVESTIGATOR_765034] . 
Tropi[INVESTIGATOR_421736] , CVC, an d the combination all 
reduced fibrosis to a similar extent vs. vehicle. These preclinical combination data supports 
further evaluation in humans.
Tropi[INVESTIGATOR_765018] (combination) toxicolog y data
In accordance totheInternational Conference onHarm onization (ICH)guidance on non-
clinical safet
ystudies (ICH)M3(R2) section XVII (combination drugtoxicit y testing), 4 and
13weekGLPcombination studies were performed inratstosupport thelong term clinical 
development of the 2 investigational drugs CVC and tropi[INVESTIGATOR_765035].
CVC and/or LJN452 were administered separatel y or in combination, daily  via oral gavage to 
rats for 28 day s (Study  652-9-1059).  The groups and doses were as indicated in the Table 1 - 1
below:
Table 1-1 S tudy  design 28 da y oral gavage combination study
GroupNo. of 
Anim alsCVC Dose 
Level
(mg/kg/ 
day)CVC Dose 
Concentration
(mg/mL)LJN452 
Dose Level
(mg/kg/ 
day)LJN452 Dose 
Concentration
(mg/mL) M F
1 (Control) 10 10 0 0 0 0
2 (CVC low) 10 10 30 6.0 0 0
3 (CVC high) 10 10 100 20.0 0 0
4 (LJN452 low) 10 10 0 0 0.03 0.006
5 (LJN452 High) 10 10 0 0 1.0 0.2
6 (CVC+LJN452) (low) 10 10 30 6.0 0.03 0.006
7 (CVC+LJN452) (high) 10 10 30 6.0 1.0 0.2
Source: Study 652-9- 1059
CVC = Cenicriviroc; F = Female; M = Male

[COMPANY_001] Confidential Page 28
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Administration of CVC alone or in combination with LJN452 was generally  well-tolerated
when administered via oral gavage for 28 days. The only effects noted during in-life phase were 
slightly  decreased mean body  weight and body weight change for males administered 1.0 
mg/kg/day  LJN452, alone or with 30 mg/kg/day  CVC and slightly  decreased food consumption 
for males administered 1.0 mg/kg/day  LJN452 with 30 mg/kg/day  CVC. 
Clinical pathology  changes were seen primarily  in animals administered LJN452 and consistent 
with the changes reported in previous studies with LJN452 and with the expected pharmacology 
of the drug. Most of the test-article related clinical chemistry  effects may be associated with 
expected pharmacology  of the test article(s). 
Clinical pathology  changes in animals administered CVC included minimally  to mildly  lower 
absolute monocy te counts which was attributed to the pharmacology of CVC (CCR2 
antagonism) and was not noted in animals administered L JN452 alone. 
Based on the microscopic findings, primary  target tissues for LJN452 were the liver, kidney, 
and intestines as previously  reported in other studies with LJN452 alone. These findings may 
be attributable to the pharmacologic activity  of LJN452, as FXR is highly  expressed in the liver, 
kidney , and intestines. Secondary findings, consistent with stress, were observed in the thymus 
and prostate in animals administered LJN452, which correlated with decreased individual 
and/or group thymus and prostate weights, respectivel y, as well as decreased individual 
terminal body  weights. 
In conclusion, administration of CVC alone caused no microscopic findings indicative of 
toxicity  and administration of CVC in combination with of LJN452 had no impact on toxicity  
of LJN452.
CVC and LJN452 were administered incombination daily  via oral gavage to rats for at least 13 
weeks to assess the reversibility , persistence, or delay ed occurrence of any effects after an 8-
week recovery  phase ( Study 1984- T01- 052).
The groups and doses are presented in the Table 1 -2below:
Table 1-2 S tudy  design 13 week s oral gavage combination study
Group
Sub-
groupNo. of 
Anim alsCVC 
Dose 
Level
(mg/kg/ 
day)CVC Dose 
Concentration
(mg/mL)LJN452 
Dose 
Level
(mg/kg/ 
day)LJN452 Dose 
Concentration
(mg/mL) M F
1 (Control) 1 (Tox) 15 15 0 0 0 0
2 (TK) 3 3
2 (Low) 1 (Tox) 15 15 3 0.6 0.03 0.006
2 (TK) 6 6
3 (High) 1 (Tox) 15 15 30 6 0.5 0.1
2 (TK) 6 6
Source: Study 1984 -T01-052
CVC = Cenicriviroc; F = Female; M = Male; Tox = Toxicity; TK = Toxicokinetic.

[COMPANY_001] Confidential Page 29
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
No LJN452 or CVC related effects on mortality , clinical observations, ophthalmic observations, 
functional observational battery  (neurobehavioral observations, elicited behaviors, or open field 
observations) occurred.
During the dosing phase, males administered ≥ 3/0.03 mg/kg/day (CVC/L JN452) gained 
slightly  less weight compared to controls, while females gained more. Both effects reversed 
during the recovery  phase.  
Several relativel y minor, CVC -and L JN452 -related cl inical pathology  findings were observed 
at the terminal sacrifice in animals administered ≥ 3/0.03 mg/kg/day  CVC/L JN452. These 
findings were attributed to the pharmacologic activity  of CVC (CCR2 antagonism/decreased 
monocy tes) or LJN452 (FXR agonism); those changes were similar to the one observed with 
the single agents (see above).
At the terminal sacrifice, CVC -and LJN452 -related microscopic findings occurred in the liver, 
kidney , intestine (cecum, duodenum, and ileum) and the spleen. In the liver, minimal to 
moderate hepatocy te hypertrophy  and periportal vacuolation was observed microscopi[INVESTIGATOR_1306] y in
animals administered 30/0.5 mg/kg/day . Higher liver weights correlated with hepatocellular 
hypertrophy  and hepatocy te vacuolation in animals administered 30/0. 5 mg/kg/day , 
hepatocellular hypertrophy  in females administered ≥3/0.03 mg/kg/day .  In the intestine, an 
increased incidence of crypt/gland ectasia was noted in the cecum, duodenum, and ileum of 
animals administered 30/0.5 mg/kg/day . In the kidney , a CVC andLJN452 -related increased 
incidence of basophilic tubules was noted in the cortex of males administered 30/0.5 mg/kg/day . 
Higher spleen weights correlated with the microscopic finding of increased marginal zone size 
in animals administered 30/0.5 mg/kg/d ay; this change is consistent with the effect of a 
pharmacological inhibition of CCR2 by [CONTACT_765091] (Flaishon 2004 et al). 
At the recovery 
sacrifice, no CVC and LJN452 -related microscopic findings were observ ed, indicating 
reversibility  of the changes observed during the dosing phase. The NOAEL is30/0.5 mg/kg/day 
CVC /LJN452 )
.
Overall, the toxicity  findings observed during the single agent studies and the combination 
studies were similar. The changes in clinical pathology  were either due to the CCR2 
pharmacology  (decreased monocy tes) or FXR agonism and were similar in the combination 
studies compared to the single agent studies. The primary  target organs observed 
microscopi[INVESTIGATOR_1306] y were the liver, kidney  and gastrointestinal tract and were similar in the 
combination studies compared to the single agent studies. The nature and the severit y of the 
findings in these organs were also similar. In addition, minimal to mild increased marginal zone 
in the spleen was obser ved after 13 weeks of treatment at 30/0.5 mg/kg/day  CVC/L JN452. 
Although the mechanism of action has not been determined, this change is consistent with a 
pharmacological inhibition of CCR2 in the spleen (Flaishon 2004 et al) .The NOAEL in the 13 
week study was the high dose of 30/0.5 mg/kg/day CVC /LJN452 .
In conclusion, the findings in the 4 -and 13
-week combination therapi[INVESTIGATOR_765036]/or with their expected 
pharmacology .
Clinical tropi[INVESTIGATOR_765018] –drug -drug interaction r esults 
Asingle site, randomized, parallel 3-arm, doubl e -blind, double- dummy drug-drug interaction 

[COMPANY_001] Confidential Page 33
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
with CVC inclinical trials.
Tropi[INVESTIGATOR_765037] c enicriviroc –clinical DDI and f ood 
The tropi[INVESTIGATOR_421736] + CVC drug-drug interaction study  CLJC242A2101 in health y subjects 
suggested that co-administration of CVC reduces tropi[INVESTIGATOR_765038] (both Cmax and AUC 0 -
24h) by [CONTACT_2902] 35% .No safet y concerns were identified at the doses of [ADDRESS_1048638] for 
14 days. In addition, anacross -study  exploratory  comparison indicated that tropi[INVESTIGATOR_765039] (both Cmax and AUC) at 60 µg administered fasted (study  CLJN452X2101) is similar 
to that at the same dose administered following a st andard breakfast (study  CLJC242A2101).
In summary , as compared to the fasted status, a high -fat meal increases tropi[INVESTIGATOR_765040] 
a standard meal appears notto. It is recommended that NASH patients, in this study , will be 
dosed following a standard m eal without high fat (i.e. per AHA diet see appendix 17 ).
Tropi[INVESTIGATOR_765018] (combination) -safety  considerations
In the DDI study  (CLJC242A2101) the safet y and tolerability  of th e combination treatment of
tropi[INVESTIGATOR_421736] + CVC were found to be comparable to those of each of the mono therap y treatment. 
No additional particular safet y considerations are expected for the combination of tropi[INVESTIGATOR_765041], beyond those previously  observed for each of the indivi dual monotherapi[INVESTIGATOR_014] 
(see section 1.1andsection 3.6for risks). As both drugs may increase liver transaminases, there 
is a potential fo r an additive effect, thus close liver monitoring is included.  Diarrhea has been 
identified as a non-serious adverse effect for cenicriviroc and is a possible (but unconfirmed) 
adverse effect of tropi[INVESTIGATOR_765042].
Tropi[INVESTIGATOR_765018] (combination) -rationale 
Due to the multifactorial etiology  of NAFLD/NASH and limited monotherapy  results so far, 
thecombination therap y of compounds with different mechanisms of actions may provide more 
effective therap y for NASH patients. 
This study will combine thepotent FXR agonist (anti-steatotic, anti-inflammatory  and anti-
fibrotic) tropi[INVESTIGATOR_765043]2/5 inhibitor (anti-inflammatory  and anti-fibrotic) cenicriviroc .
The preclinical animal study  STAM mouse models of diet induced NASH, shows that 
combination therap y of tropi[INVESTIGATOR_765044], ballooning, 
and inflammation .
Both tropi[INVESTIGATOR_765045] 2 and 
phase 3 clinical trials, respectivel y CLJN452A2202 (clinicalTrials.gov Identifier: 
[STUDY_ID_REMOVED]) and AURORA (clinicalTrials.gov I dentifier: [STUDY_ID_REMOVED]) , and to date have 
shown improvements on biomarkers and in case of cenicriviroc improvements in liver fibrosis 
in NASH patients. 
In summary , these two drugs have different mechanisms of action (FXR and CCR2/5 inhibitor), 
and this multi target approach may  lead to greater efficacy  than monotherapy  alone. 

[COMPANY_001] Confidential Page 34
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
1.2 Purpose
The purpose of this study  is to assess the safety , tolerability , efficacy   of 
two regimens of tropi[INVESTIGATOR_765018] (CVC) (further described as tropi[INVESTIGATOR_421736] +CVC) 
compared to monotherapi[INVESTIGATOR_765046] a nd liver fibrosis. Data 
from this study  will be used to evaluate whether further development of combination therap y 
with tropi[INVESTIGATOR_421736] +CVC in the treatment of patients with non-alcoholic steatohepatitis (NASH) 
and liver fibrosis is beneficial.
[ADDRESS_1048639]
ives and endpoints
2.1 Objectives and related endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary Objective(s) Endpoint(s) for primary objective(s) 
To evaluate the safety and tolerability of  
tropi[INVESTIGATOR_421736] +CVC in patients with NASH and 
fibrosis (stage 2 or3 as pe r NASH CRN 
histological score, F2/F3 ) by [CONTACT_725625], vital signs and laboratory values during 
[ADDRESS_1048640] and changes in vital 
signs and laborator y values over 48 weeks of 
treatment
Secondary Objective(s) Endpoint(s) for secondary objective(s)
To characterize the efficacy of tropi[INVESTIGATOR_421736] + CVC 
in patients with NASH with fibrosis stage F2/F3
as assessed by [CONTACT_765092] 
48 weeks of treatment compared to 
monotherapi[INVESTIGATOR_014] ( tropi[INVESTIGATOR_765021]) compared 
to baseline biopsyProportion of patients who have at least a one 
point improvement in fibrosis 
Proportion of patients with resolution of 
steatohepatitis 

[COMPANY_001] Confidential Page 35
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J

[COMPANY_001] Confidential Page 36
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
[ADDRESS_1048641] dose of study  treatment. The total study 
duration is up to 62 weeks.
The screening period starts from the time of the signing of informed consent and continues for 
up to 10weeks when all inclusion/exclusion criteria have been evaluated and all baseline 
assessments have been performed. 
Patients are eligible to participate in the study  if they  have histological evidence of NASH and 
liver fibrosis stage 2 or 3 (NASH clinical research network (CRN) staging criteria) 

[COMPANY_001] Confidential Page 38
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
3.2 Rationale for study  design
A [COMPANY_001] sponsored Phase 2 trial (CLJN452A2202 ) is ongoing, with the purpose to identify 
the appropriate doses of tropi[INVESTIGATOR_765047] , the tropi[INVESTIGATOR_765048] y planned doses being utili zed in that study (CLJN452A2202).
The availability  of long term non-clinical toxicity  data supports the treatment duration with 
tropi[INVESTIGATOR_765049] 48 weeks and the inclusion of a histological endpoint (GLP –toxicology  studie s 
of 13 weeks duration, and longer term GLP -toxicology  of 26 weeks duration in rat and 39 weeks 
in dog studies (tropi[INVESTIGATOR_765050])
. For tropi[INVESTIGATOR_765051] y a long term efficacy  study 
(CLJN452A2202) is ongoing, with 48 week treatment period and safet y follow -up to Week 52
which will provide the opportunity  for evaluation of histological improvement by [CONTACT_765093] 48.
Paired liver biopsies at baseline and at Week 48 will be included for all patients in this study.  
Inclusion criteria will require histologic evidence consistent with NASH and fibrosis level, F2 
or F3 at baseline, based on liver biopsy  (as determined by  a central reader) obtained during the 
screening period or within 6 months before randomization.  
CVC at a dose of 150 mg once dailyis currentl y in Phase 3 
(AURORA ) clinical development 
for the treatment of liver fib rosis in adults with NASH and in Phase 2 development in subjects 
with primary  sclerosing cholangitis (PSC). Overall, over [ADDRESS_1048642] been exposed to 
CVC in both ongoing and completed studies ( CVC IB).
In a 2-year placebo -controlled Phase 2b study  (652- 2-203- CENTAUR, Friedman et al 2017 ), 
[ADDRESS_1048643] been lacking significant 
efficacy . The expectation of a combined therapy  is to improve efficacy  based on the 
combination of different mechanisms of action. In this study  we are combining a potent FXR 
(anti-steatotic, anti -inflammatory and anti -fibrotic) and a CCR2/5 inhibitor (anti
-inflammatory
and anti -fibrotic).
The patient population will be described in more detail in Section 4 below .
3.3 Rationale for 
dose/regimen, route of administration and duration 
of treatment 
Tropi[INVESTIGATOR_765052] y in study  CLJN452A2202. The 
initial range of doses of [ADDRESS_1048644]-in-Human study  CLJN452X2101 , and preclinical 
experience ( tropi[INVESTIGATOR_765050] ).
The DMC for study  CLJN452A2202, upon review of CLJN452A2202 Part A data, 
recommended to investigate doses higher than 90 µg. The current non -clinical safet y profile of 

[COMPANY_001] Confidential Page 40
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
3.5 Purpose and timing of interim analy ses/design adaptations
3.6 Risks and benefits
As well as the risks and potential risks described in the tropi[INVESTIGATOR_765021] (TBR -652) 
Investigators’ Brochures, there may be unknown risks to tropi[INVESTIGATOR_765053].
Tropi[INVESTIGATOR_765054] a highl y potent and specific agonist of the 
Farnesoid X Receptor (FXR) and data acquired in the First-in-Human study  CLJN452X2101
and in nonclinical toxicology  studies the risk- benefit assessment of tropi[INVESTIGATOR_765055]:
Transient and asymptomatic increases in ALT have 
been identified as an adverse reaction to 
tropi[INVESTIGATOR_765056]. Potential toxicities to be considered for tropi[INVESTIGATOR_765057], gastrointestinal effects, coagulation effects, renal function abnormalities, 
and embry o-fetal toxicit y. In addition it is anticipated that tropi[INVESTIGATOR_765058]. Guidelines for the 
evaluation 
and detection of these potential toxicities and for their management and for minimization of 
risk if they  do arise are discussed in the tropi[INVESTIGATOR_765059]’s Brochure.
Tropi[INVESTIGATOR_765060] (reduced 
synthesis and increased detoxification), lipid profile (lowering triglycerides) and anti-fibrotic 
activiti es (reduced hepatic fibrosis) may improve pathophy siology  and patient outcomes over 
longer term treatment in longer- term development studies. 
In addition to usual study  monitoring, patients’ liver tests will be followed closely , especiall y 
early in therap y, in conjunction with the Data Monitoring Committee (DMC ), including 
frequent checks of a liver safet y panel and drug dosage dose reduced or discontinued if 
necessary . 
Cenicriviroc
CVC is currently  in Phase 3 clinical development for the treatment of liver fibrosis in adults 
with NASH and in Phase 2 development in subjects with primary sclerosing cholangitis (PSC). 
Overall, over [ADDRESS_1048645] been exposed to CVC in both ongoing and completed studies, 
with a maximum exposure available of ≥48 weeks of treatment in approximately 260 subjects. 
CVC doses ranged from 25 mg to 900 mg across all CVC studies. 
Study  652-2-203 ( CENTAUR )is an ongoing 2 -year placebo -controlled Phase 2b study  in 289 
adult patients with liver fibrosis and NASH. CVC demonstrated significant antifibrotic benefits 
in adult subjects with NASH, in addition to decreasing markers of systemic inflammation after 
only one year of treatment ( CVC IB ).
Toxicology  studies showed no target organ toxicity , thus no adverse 
liver findings, in mice or 
monkey s. In rats, the liver was the primary  target organ identified in repeat dose studies, with 
biliary  hyperplasia being the primary  finding. Overall, the risk for hepatobiliary  effects due to 
CVC appears to be low. The nonclinical data suggest that CVC will not adversel y affect the 
liver at or near clinical exposures. L iver f indings were present in only  1 of 3 species and when 

[COMPANY_001] Confidential Page 42
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
[ADDRESS_1048646] of approximately  200 adult male and female patients with 
histologic evidence of NASH and fibrosis (stage 2 or 3 as per NASH CRN histological score, 
F2/F3) ; see Inclusion and Exclusion criteria for details.
The study  will be conducted in approximately  90 centers worldwide. Since a screening failure 
rate is expected to be around 66%, ap proximately  [ADDRESS_1048647] fulfill all of the following criteria:
1.Written informed consent must be obtained before any  assessment is performed. 
2. Male and female patients 18 years or older (at the time of the screening visit). Patients 
must weigh at least 50 kg (110 lb) and no more than 200 kg (440 lb) to participate in the 
study .
3. Able to communicate well with the investigator, to understand and comply with the 
requirements of the study.
4.Adequate liver biops y sample for evaluation by a central r eader.
5.Presence of NASH as demonstrated by  [CONTACT_765094]  -NASH 
with fibrosis stage F2/F3
, demonstrated on liver biopsy with evaluation by [CONTACT_765095]. Alternativel y, a historical biopsy can be used if performed 
within 6 months prior to screening and evaluated by  [CONTACT_39582] , if:
the patient has been receiving an y of the therapi[INVESTIGATOR_180568] 5-4, the dose must 
have been stable (since 1 month before the biops y up to and including screening) ,
the patient’s weight has been stable (maximum weight loss of 10% since biopsy  up to 
and including s
creening).
4.2 Exclusion criteria
Patients fulfilling an y of the following criteria are not eligible for inclusion in this study : 
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible patients.
1.Use of other investigational drugs within 5 half-lives of enrollment or within 30 days 
whichever is longer.
2.History  of hy persensitivity  to any  of the study  drugs or its excipi[INVESTIGATOR_201014].
3. Previous 
exposure to elafibranor, CVC, tropi[INVESTIGATOR_421736], obeticholic acid (OCA), LMB763 or 
other FXR agonist.
4.Participated in a clinical trial and treated with any investigational product being evaluated 
for the treatment of liver fibrosis or NASH in the 6 months before screening (subjects 
documented to be assigned to placebo in such trials may  be eligible immediately  following 
completion of their participation in the previous trial).

[COMPANY_001] Confidential Page 43
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
5.Patients taking medications prohibited by [CONTACT_760]. An overview of prohibited 
medica tions is given in Table 5-2, and the summary  of medications permitted only if on 
stable dose is in Table [ADDRESS_1048648] 5 years, 
regardless of whether there is evidence of local recurrence or metastases.
7.Pregnant or nursing (lactating) w omen.
8.Women of child- bearing potential, defined as all women physiologically  capable of 
becoming pregnant, unless they  are using highl y effective methods of contraception during 
dosing and for 30 days after stoppi[INVESTIGATOR_765061]/or CVC medication. Highl y effective 
contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the subject). 
Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post -ovulation methods) and 
withdrawal are not accepta ble methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) total hysterectom y or tubal ligation at least six weeks before taking 
investigational drug. In case of oophorectom y alone, only when the reproductive status of 
the woman has been confirmed by  [CONTACT_104].
Male sterilization (at least 6 months prior to screening). For female subjects on the study , 
the vasectomized male partner should be the sole partner for that su bject.
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem (IUS) or 
other forms of hormonal contraception that have comparable efficacy  (failure rate <1%), 
for example hormone vaginal ring or transdermal hormone contraception
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_1048649] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate, history  of vasomotor symptoms) or have had surgical bilateral oophorectom y (with 
or without hysterectom y), total hysterectom y or tubal ligation at least six weeks ago. In the case 
of oophorectom y alone, only when the reproductive status of the woman has been confirmed 
by [CONTACT_765096]. 
Sexually  active males must use a condom during intercourse while taking drug and for 30 days 
after stoppi[INVESTIGATOR_765062]/or CVC medication and should not father a child in this period. A 
condom is required to be used also by [CONTACT_230769]. 
9.Current or history  of significant alcohol consumption for a period of more than 3 
consecutive months within 1 year prior to screening (significant alcohol consumption is 
defined as more than 20 g/day  in females and more than 30 g/day  in males, on average) 
and/or a score on the modified AUDIT questionnaire ≥ 8

[COMPANY_001] Confidential Page 44
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
10.Inability  to reliabl y quantify  alcohol consumption based upon local study  physician 
judgment
11.History  or evidence of ongoing drug abuse, within the last 6 months prior to randomization. 
Marijuana use is not allowed if it is determined to be medically  inappropriate by [CONTACT_1275] 
12. Prior or planned (during the study  period) bariatric surgery  (e.g. gastroplasty , roux-en-Y 
gastric b ypass) 
13. Uncontrolled diabetes defined as HbA1c ≥ 9% at screening
14.Clinical evidence of hepatic decompensation or severe liver impairment as defined by [CONTACT_765097] y of the following abnormalities (confirmed at screening visit 2):
Serum albumin <  3.2g/dL
International Normalized Ratio ( INR)> 1.3
Total bilirubin > 
1.3 mg/dL (including Gilbert’s sy ndrome)
ALT or AST > 5× ULN 
Alkaline phosphatase > 300 IU/L
History  of esophageal varices, ascites or hepatic encephalopathy
Splenomegal y 
15.Previous diagnosis of other forms of chronic liver disease:
Hepatitis B as defined by [CONTACT_107077] B surface antigen (HBsAg) or hepatitis 
B core antibod y (HBcAb) positive
Hepatitis C antibody  (HCVAb) positive with the following 2 exceptions: 
Subjects previously  treated for viral hepatitis C with at least a 3-year period since 
documented sustained virologic response at Week 12 (post -treatment) may be 
eligible if all other eligibility  criteria are met
Subjects with presence of hepatitis C antibo dy but negative hepatitis C virus (HCV) 
ribonucleic acid (RNA) without treatment (i.e., spontaneous clearance) may be 
eligible if all other eligibility  criteria are met
History  of autoimmune liver disease:
Primary  biliary  cholangitis as defined by  [CONTACT_765098] 2 of these criteria:
Biochemical evidence of cholestasis based mainly on alkaline phosphatase elevation
Presence of anti -mitochondrial antibodies (AMA)
Histologic evidence of nonsuppurative destructive cholangitis and destruction of 
interl obular bile ducts
Primary  sclerosing cholangitis

[COMPANY_001] Confidential Page 45
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
History  of Wilson's disease 
History  of Alpha -1-antitrypsin (A1AT)  deficiency 
History  of hemochromatosis or iron overload.
Drug -induced liver disease as defined on the basis of ty pi[INVESTIGATOR_765063]
Known bile duct obstruction
Suspected or proven liver cancer
Any other t ype of liver disease other than NASH 
16.Calculated eGFR less than 60 mL /min/1.73m2(using the MDRD formula)
17.History
 of biliary  diversion 
18.History  of liver transplantation or planned liv er transplant
19.Known positivity  for Human I mmunodeficiency  Virus (HIV) infection
20.Any other condition which, in the opi[INVESTIGATOR_871], would impede compliance or 
hinder completion of the study
21.History  or current diagnosis of ECG abnormalities indicating significant risk of safet y for 
patients participating in the study  such as:
Concomitant clinically  significant cardiac arrhythmias, e.g. sustained ventricular 
tachycardia, and clinically  significant second or third degree AV block without a 
pacemaker
QTcF interval of greater than 450 ms at screening
History  of familial long QT sy ndrome or known family  history  of Torsades de Pointes
22.History of inflammatory  bowel disease 
23.Patients who are not candidates for liver biops y
24. Presence of cirrhosis on li ver biopsy  (F4 by  [CONTACT_765099]) or medical history  
25.Patients with an abnormal platelet count (see reference ranges in central laborator y manual) 
5 Treatment
5.1 Stud y treatment
5.1.1 Investigational and control drugs
Tropi[INVESTIGATOR_421736]:
Dosage form: [ADDRESS_1048650] gelatin capsules.
Presentation: Bottles

[COMPANY_001] Confidential Page 46
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Tropi[INVESTIGATOR_765064]:
Dosage form: hard gelatin capsules
Presentation: Bottles
CVC:
Dosage form: 150 mg coated tablet
Presentation: Bottles
CVC Placebo:
Dosage form: coated tablet
Presentation: Bottles
[COMPANY_001] will provide sufficient supplies of tropi[INVESTIGATOR_765065] (or more).
5.1.2 Additional treatment
No additional treatment beyond investigational drug and placebo is provided in this trial.
5.2 Treatment arms
Patients (n = 200) will be assigned at baseline visit to one of the following 4 treatment arms in 
a ratio of 1:1:1:1 in a blinded manner. Placebo capsules/tablets will be given in each treatment 
arm where necessary  to maintain blinding.
Arm A: tropi[INVESTIGATOR_421736] 140 μg, once -daily
Arm B: CVC 150 mg , once -daily
Arm C: tropi[INVESTIGATOR_421736] 140 μg + CVC 150 mg , once -daily
Arm D: tropi[INVESTIGATOR_421736] 90 μg + CVC 150 mg , once -daily
In order to maintain the blind, placebo capsules matching tropi[INVESTIGATOR_421736] 10, 30, 90 and 100µg 
capsules and placebo tablets matchin g CVC 150mg will be given to patients as indicated in
Table 5-1, so that all patients will receive 3capsules and 1 tablet per day. One capsule/tablet 
from each of the 4bottles dispensed should be taken with food (e.g. immediatel y following a 
meal )and at about the same time each day . 
5.3 Treatment assignment and randomization
At baseline visit, all eligible patients/subjects will be randomized via Interactive Response 
Technology  (IRT) to one of the treatment arms. The investigator or his/her delegate will contact 
[CONTACT_286774]/exclusion criteria. The IRT 
will assign a randomization number to the patient, which will be used to link the patient to a 
treatment arm and will specify  a unique medication number for the first package of study  drug 
to be dispensed to the patient. The randomization number will not be communicated to the caller.

[COMPANY_001] Confidential Page 48
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
If the subject fails to be treated for any  reason, the IRT must be notified within [ADDRESS_1048651] was not treated. The reason for not being treated will be entered on the appropriate 
eCRF.
5.5.2 Dispensing the study drug 
Each stud y site will be supplied with study  drug .
The study  drug packaging has a 2-part label. A unique medication number is printed on each 
part of this label which corresponds to a certain treatment . Investigator staff will identify  the 
study  drug package(s) to dispense to the patient by [CONTACT_765100](s). Immediately  before dispensing the package to the patient, investigator 
staff will detach the outer part of the label from the packaging and affix it to the source 
document (Drug Label Form) for that patient’s unique subject number. 
For patients who are unable to come to the study  site for their end-of-treatment visit ( week-48)
and the liver biopsy  visit as schedule d per study protocol due to the COVI D-19 pandemic :-the
investigator may consider to extend the study  treatment to allow the visit (including liver biops y) 
to be performed later. This can be done using the following stepwise approach:
The study  medication dispensed at week [ADDRESS_1048652] about 2 weeks’ excess 
medication. The liver biopsy  visit can be delay ed until the medication runs out. 
If this is not sufficient, an unscheduled visit can be performed (by [CONTACT_32627] ) 
and an additional 4-week supply  of study  medication requested via  IRT and send the 
medication to patient’s home address (if considered safe and appropriate). If feasible, 
central or local lab assessments (Liver tests, Serum BUN & Creatinine) should be 
performed ev
ery 8 weeks to monitor the patient’s safet y.
If that is still not sufficient, a second 4-week supply  of study  medication can be 
requested via IRT
. 
The Investigator should ensure that this study  treatment extension is discussed with the 
impacted patients t horoughl y, including the possible risks and benefits of longer treatment 
duration. The discussion and the patient’s willingness to extend the study  treatment duration 
should be recorded in the source documents.
5.5.3 Handling of study  and additional treatment 
[IP_ADDRESS] Handling of study  treatment 
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and designees 
have access. Upon receipt, all study  treatment must be stored according to the instructions 
specified on the labels. Clinical supplies are to be dispensed only in accordance with the 
protocol. Technical complaints are to be reported to the respective [COMPANY_001] CPO Qualit y 
Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the patient except for the medication number .

[COMPANY_001] Confidential Page 49
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
[CONTACT_744287]. Patients/subjects will be asked to 
return all unused study treatment and packaging at each visit or at the time of discontinuation 
of study  treatment. 
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  treatment, packaging, drug labels, and a copy of the completed drug 
accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.
[IP_ADDRESS] Handling of additional treatment 
Not applicable.
5.5.4 Instructions for prescribing and taking study treatment 
Patients 
should be instructed to take the dose of study  medication daily ,in the morning ,with 
food (e.g. immediatel y after a meal) at approximately  the same time each dayexcept the days 
with a morning visit. On the days where there are study  visits, ifthe visit is in the morning time, 
the patients should take their doses at the clinic following a meal. From the baseline day
onwards , patients will be instructed to take 1 tablet and 3capsules each day during the duration 
of the study .
The patient will be dispensed 4bottles for each 4 weeks period and should take o ne tablet from 
one bottle and 3capsules (one from each of the other 3bottles) .
Table 5-1 Overview of treatment -type and number of capsules and tablets 
taken per day
Treatment 
armCVC 150 
mgtabletCVC 
placeboTropi[INVESTIGATOR_421736] 
10µg 
capsuleTropi[INVESTIGATOR_421736]
30µg 
capsuleTropi[INVESTIGATOR_421736] 
90µg 
capsuleTropi[INVESTIGATOR_421736] 
100µg 
capsuleTropi[INVESTIGATOR_765066]
A 0 1 1 1 0 1 0
B 1 0 0 0 0 0 3
C 1 0 1 1 0 1 0
D 1 0 0 0 1 0 2
Dosing recommendations:
Patients should take the medications in the morning with food (e.g. immediately  after a 
meal) and at about the same time each day .
Patients should be instructed to swallow the capsules whole and not to chew them.
If vomiting occurs during the course of treatment, no re- dosing of the patient is allowed 
before the next scheduled dose.
Missed doses should not be made up.
All kits of stud y treatment assigned by  [CONTACT_317605]/databased in the I RT.
The investigator must promote compliance by [CONTACT_18610]’s safet y and the 

[COMPANY_001] Confidential Page 50
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
validity  of the study . It should be emphasized to the patient that the study medication bottles 
are not identical; the patient must take one tablet or capsule from each bottle each day. The 
patient must also be instructed to contact [CONTACT_765101]/she is unable for any reason to 
take the study  treatment as prescribed .
[IP_ADDRESS] Dietary  restrictions 
No alcohol consumption is allowed for 8 hours before each dose of study  medication. Alcohol 
should also not be consumed for 8 hours before each study visit .
To keep the fat intake as constant as possible, patients participating in this study  will be 
instructed to carefully  adhere to American Heart Association (AHA) diet or local equivalent if 
there is a country  specific recommended diet (Appendix 5). Patients will be asked about dietary 
compliance to the AHA diet (or local equivalent) as outlined in Table [ADDRESS_1048653] the patient to notify the study  site about any new medications 
he/she takes after the patient was enrolled into the study . All medications, procedures and 
significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered 
after the patient was enrolled into the study  must be recorded in the appropriate e
CRF.
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt the investigator should contact [CONTACT_18614] a patient or allowing a new medication to be started.
5.5.8 Prohibited medication
Use of the treatments displayed in the be low table ( Table 5 -2) is NOT allowed after the start of 
investigational drug. 

[COMPANY_001] Confidential Page 51
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Table 5-2 Prohibited medications
Medication Guidance
Inhibitors, inducers and sensitive substrates of drug metabolizing enzymes
Specific UGT1A1 inhibitors:
atazanavir, gemfibrozil, indinavir, itraconazole, ketoconazole, 
manidipi[INVESTIGATOR_050], and zafirlukastProhibited from first drug 
intake to end-of-study visit
Herbal remedies inhibiting UGT1A1: 
Silybum marianum (sylamarin, milk thistle) and Valeriana 
officinalis (valerian)Prohibited from first drug 
intake to end -of-study visit
Non-selective UGT inhibitors: 
diclofenac, probenecid, valproic acid Prohibited  from first drug 
intake to end -of-study visit
Strong CYP3A4 inhibitors:
VIEKIRA PAK2, indinavir/ritonavir, tipranavir/ritonavir, ritonavir, 
cobicistat (GS -9350), indinavir, ketoconazole , troleandomy cin, 
telaprevir , danoprevir/ritonavir , elvitegravir/ritonavir , 
saquinavir/ritonavir , lopi[INVESTIGATOR_054]/ritonavir, itraconazole , 
voriconazole ,mibefradil , LCL161 , clarithrom ycin, posaconazole , 
telithrom ycin, grapefruit juice , conivaptan , nefaz odone , 
nelfinavir , saquinavir , idelalisib , boceprevir ,darunavir/ritonavir .Prohibited use from first drug 
intake to end -of-study visit
Strong CYP3A4 inducers:
avasimibe, carbamazepi[INVESTIGATOR_050], phenytoin, rifampin, St. John’s wort
(Hypericum perforatum ), rifabutin, phenobarbital, mitotane, 
enzalutamide.Prohibited fr om first drug 
intake to end -of-study visit
Strong CYP2C8 inhibitors:
gemfibrozil, clopi[INVESTIGATOR_765067].Prohibited from first drug 
intake to end -of-study visit
Sensitive CYP3A4 substrates with narrow therapeutic index (i.e. 
drugs that should not be co -administer ed with weak CYP3A4 
inhibitors ):
astemizole, cisapride, c yclosporine, dihydroergotamine, 
ergonovine, ergotamine, ergotamine , methylergonovine, 
pi[INVESTIGATOR_3924], quinidine, sirolimus, tacrolimus, terfanadine, 
thioridazine . Prohibited from first drug 
intake to end -of-study visit
Sensitive CYP3A4 substrates exceptions: 
midazolam , triazolamUse only allowed for sedation 
on the day of the liver biopsy 
or for surgical outpatient 
procedures. If given after 
intake of study drug, the first 
dose should be reduced by 
50% of the recommended 
dose and titrated according to 
the desired clinical response.
Sensitive CYP3A4 substrates exceptions: 
intravenous alfentanil or fentanylUse is allowed for sedation on 
the day of screening biops y 
but is not allowed for any 
procedure af ter intake of 
study drug.
Sulfasalazine and methotrexate Prohibited from first drug 
intake to end -of-study visit

[COMPANY_001] Confidential Page 52
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Medication Guidance
Vitamin E Prohibited at doses 
> 400 IU/day 
[IP_ADDRESS] Drugs to be used with restrictions
If required ,the medications specified on Table 5-3should be used with caution, at the lowest 
dose possible and for the shortest duration possible considering individual subject risk-benefit 
considerations. Clinical monitoring and dose titration are recommended t o achieve the desired 
clinical response. Other medications of a similar class should be considered if possible. Consult 
the individual medication prescribing information for additional guidance. 
Table [ADDRESS_1048654] be taken with caution
Medication Guidance
Acid- reducing agents 
(H2receptor 
antagonists, proton -
pump inhibitors)Acid reducing agents should be administered at least 2 hours after study 
drug administration. W hen possible, use of an H 2receptor antagonists 
(except cimetidine) or antiacids is preferred over a proton -pump 
inhibitor. It is recommended to start with the lowest dose of these agents 
and titrate acco rding to clinical response.
H2receptor antagonists (e.g. famotidine or ranitidine) should preferably 
be given from 2 to 12 hours after administration of study drug at a dose 
that does not exceed doses comparable to famotidine 40 mg daily.
Antiacids (e.g. alum inium hydroxide, calcium carbonate, magnesium 
carbonate, magnesium hydroxide or bismuth subsalicylate) should 
preferably be given at least 4 hours after administration of study 
PPIs (e.g., omeprazole, lansoprazole, esomeprazole, pantoprazole, 
rabepraz ole, or delansoprazole) should preferably be given 
approximately 3 hours after administration of study drug at a dose that 
does not exceed doses comparable to omeprazole 20 mg daily. 
Lipid lowering agents The maximum recommended daily doses  of atorvasta tin, simvastatin,
lovastatin (CYP3A4 substrates), pravastatin (CYP3A4 substrate and 
weak CYP2C8 inhibitor )and rosuvastatin (BCRP substrate) are
restricted as follows: atorvastatin [ADDRESS_1048655] atin 10 mg ; pi[INVESTIGATOR_765068].
CVC may increase the exposure of rosuvastatin and simvastatin and 
patients taking these drugs concomitantly could be at increased risk for 
adverse effects. Monitor patients closely for sy mptoms of m yopathy or 
liver injury.
PDE5 inhibitors The recommended starting doses for these CYP3A4 substrates are as 
follows: sildenafil [ADDRESS_1048656] 1 month before the baseline biopsy
 (historical or performed during screening). 
A stable dose is defined as a dose within 25% of the baseli ne dose. 
No new use of the medications in Table 5-4is allowed between 1 month before the baseline 
biopsy and until Study  Completion .

[COMPANY_001] Confidential Page 53
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Table 5-4 Medications permitted only  if dose is stable within 25 percent of 
baseline dose
Medication
Oral anti -diabetic medications such as pi[INVESTIGATOR_051], metformin and/or sulfonylureas
GLP-1 agonists such as liraglutide, exenatide , lixisenatide, albiglutide or dulaglutide  
Fibrates,  niacin 
Vitamin E 
Pentoxifylline
5.5.9 Emergency  breaking of assigned treatment code 
It is the investigator’s responsibili ty to ensure that there is a dependable procedure in place to 
allow access to the IRT at any  time in case of emergency . The investigator will provide:
protocol number
study  drug name (if available)
patient number
In addition, oral and written information to the subject must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at an y time.
Study  treatment must be discontinued after emergency  unblinding. The appropriate personnel 
from the study site and [COMPANY_001] will assess whether study treatment should be discontinued for 
any patient whose treatment code has been broken inadvertentl y for an y reason.
5.[ADDRESS_1048657] visit planned in the protocol.
Continuing care should be provided b y investigator and/or referring ph ysician based on patient 
availability  for follow -up. 
The investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care.
This continuing care for patients who complete 48 weeks of treatment may  include enrollment 
in an extension study , if any , to allow for therapy  beyond 48 weeks.
For all patients who discontinue treatment early or who complete treatment and do not rollover 
to an extension study  (if available), a safet y follow -up visit (visit EOS) should be conducted [ADDRESS_1048658] treatment (EOT, Week 48). The information to be collected at this follow up 
visit includes concomitant medications, adverse events, and laboratory  samples, as detailed on
Table 6-1.

[COMPANY_001] Confidential Page 54
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
5.6.[ADDRESS_1048659] discontinue study  treatment for a given patient if, on balance, he/she believes 
that continuation would negativel y impact the risk/benefit of trial participation. 
Study  treatment must be discontinued under the following circumstances: 
 Patient wish
 Pregnancy  (Ref. protocol Section 6.5.6 and Section 7.6)
 Use of prohibited treatment as per recommendations ( Section 5.5.8)
 Any situation in which study  participation might result in a safet y risk to the patient
 Emergence of the following adverse events:
Hypersensitivity  reaction to tropi[INVESTIGATOR_765069]
For ALT, AST, 
total bilirubin and/or alkaline phosphatase elevations mandating study  
treatment discontinuations ( Section 7.3 and Table 14 -1for further instructions and 
monitoring).
Specified renal events ( Section 7.4 and Table 15 -1for further instructions and 
monitoring).
Other SAE that are related to study  drug.
Other life-threatening SAE regardless of attribution to study  drug .
Any other adverse events, abnormal laboratory  values or abnormal test result that 
indicate a safet y risk to the patient.
Decompensated cirrhosis as defined b y ascites, bleeding esophage al varices, hepatic 
encephalopath y, jaundice or an y other liver decompensation related s ymptom.
The appropriate personnel from the study  site and [COMPANY_001] will assess whether study treatment 
should be discontinued for an y patient whose treatment code has b een broken inadvertently for 
any reason. Study  treatment must be discontinued after emergency  unblinding. If 
discontinuation of study  treatment occurs, the patient should NOT be considered withdrawn 
from the study. The patient should return to the clinic a s soon as possible, after discontinuation 
of study  drug, for a study  treatment discontinuation visit. Treatment discontinuation visit 
assessments detailed in the treatment discontinuation visit (TD) in Table 6-1should be 
completed and recorded in the appropriate eCRF. The investigato
r must determine the primar y 
reason for the patient’s premature discontinuation of study  treatment and record this 
information on the appropriate eCRF. The investigator must a lso contact [CONTACT_430346]’s discontinuation from study  treatment.
During the Treatment discontinuation visit (TD) , at least the following data should be collected:
new/concomitant treatments
adverse events/Serious Adverse Events
For patie nts who discontinue study  treatment prematurel y before the end of the treatment period 
for any reason other than withdrawal of informed consent, the TD visit (EOT) and Week 52 
(EOS) visits must be performed.

[COMPANY_001] Confidential Page 55
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
If stud y drug discontinuation occurs because tre atment code has been broken, refer to protocol 
Section 5.5.9.
5.6.[ADDRESS_1048660]:
•Does not want to participate in the study  anymore, and
•Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_5366] -
up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient’s study  withdrawal should be made as detailed in Table 6 -
1.
[COMPANY_001]/sponsor will co ntinue to keep and use collected study information (including an y data 
resulting from the analysis of a subject’s samples until their time of withdrawal) according to 
applicable law.
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form. 
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless perm itted by  [CONTACT_1289]. They will be stored according to applicable 
legal requirements.
5.6.[ADDRESS_1048661] show "due diligence" by 
[CONTACT_762], e.g. dates of telephone 
calls, registered letters, etc. A patient cannot be considered as lost to follow -up until the time 
point of his/her planned end of study  visit has passed.
5.6.5 Early  study termination by  [CONTACT_18620]. This may  include reasons 
related to the benefit risk assessment of participating in the study , practical reasons, or for 
regulatory  or medical reasons (including slow enrolment). Should this be necessary, the patient 
must be seen as soon as possible and treated as a prematurely  discontinued patient. The 
investigator may be informed of additional procedures to be followed in order to ensure that 

[COMPANY_001] Confidential Page 56
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
adequate consideration is given to the protection of the patient’s interests. The investigator will 
be responsible for informing the Institutional Review Board/Independent Ethics Committee 
(IRBs/IECs) of the early  termination of the trial.
6 Visit schedule and assessments
Table 6-1lists all of the assessments and indicates with an “ X” when the visits are performed. 
An ‘S’ indicates the data for that assessment are in the source
 documents at the site.
Patients who have 
been screened and have a screening visit recorded in the IRT system at the 
time that the planned enrollment number is met will be allowed to enter the trial and to be 
randomized if they  are eligible.
Patients must be see n for all visits on the designated day, or as close to it as possible. Missed or 
rescheduled visits should not lead to automatic discontinuation. Patients who prematurel y 
discontinue the study  for any reason should be scheduled for a visit as soon as possi ble, at which 
time all of the assessments listed for the final visit will be performed. At this final visit, all 
dispensed investigational product should be reconciled and the adverse event and concomitant 
medications reconciled on the appropriate eCRF.
For patients who are unable to come to the study  site for their scheduled visit due to COVID -
[ADDRESS_1048662] patient study  visits on schedule as a 
remote consultation (except the Week 48, End Of Treatment visit) and send the medication to 
patient’s home adress (if considered safe and appropriate). At these visits, the occurence of AEs 
or SAEs, change in co -medications, study  drug compliance, alcohol and AHA diet compliance  
should be determined. Patients with child bearing potential  must be reminded to perform urine 
pregnacy  test at home every  4 weeks.
Any unplanned assessments for: Vital signs, ECG, Hepatitis serology, Liver tests, Serum BUN 
and Creatinine, Coagulation panel,  
 Clinical chemistry  panel, HbA1c, Urinaly sis and Serum pregnancy  test must be 
recorded in the unplanned e
CRF.
For patients who discontinue study  treatment prematurel y before the end of the treatment period 
for any reason other than withdrawal of informed consent, the Week 48, planned End of 
Treatment (EOT) and Week 52 End of Stud y (EOS) visits must be performed.
If a patient refuses to return for these assessments or is unable to do so, every  effort should be 
made to contact [CONTACT_476], or a knowledgeable informant, by [CONTACT_37254] (i.e. certified letter) immediately. At this contact, the safety  (e.g. potential 
occurrence of AEs or SAEs) and the primary  reason for the patient’s premature withdrawal 
should be determined. Documentation of attempts to contact [CONTACT_765102].
Refer to Section 5.6for additional details regarding procedures for patients who discontinue 
study  treatment or prematurely  withdraw. 
Patients will be contact[CONTACT_15025] y evaluations during the [ADDRESS_1048663] 
administration of study  treatment. 

[COMPANY_001] Confidential Page 57
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Patients who develop medicall y important laboratory  abnormalities or medically  important 
adverse events (AE) that are considered related to study  drug will be followed bey ond the End 
of Study  visit until these events have resolved or stabilized.
The following will be considered as medically  impo rtant:
i. severe AEs ,
ii. serious AEs,
iii. hepatic and renal AEs,
iv. elevated liver enzy mes (AL T, AST or alkaline phosphat ase >2x ULN and >1.5x 
baseline).

[COMPANY_001] Confidential Page 58
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Table 6-[ADDRESS_1048664] 
Treatment 
Follow UpNotes
Week -10 
to    
-2-21
(no 
later 
than)2BSL 2 4 8 12 16 24 32 40 4816
TD/EOT52
EOS
Screening
Informed consent X
Pharmacogenetic 
informed consentX
Inclusion / Exclusion 
criteriaX X X
Demography X
Medical histor y/ current 
medical conditionsX
Protocol solicited medical 
historyX
Assessments
Physical examination3S S S S S S S S S S S S
Prior and concomitant 
medicationX X X X X X X X X X X X X
Surgical and medical 
proceduresX X X X X X X X X X X X X
Alcohol history / 
compliance with protocolX X X X X X X X X X X X X
Smoking histor y X

[COMPANY_001] Confidential Page 59
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Periods Screening Treatment Period Post 
Treatment 
Follow UpNotes
Week -10 
to    
-2-21
(no 
later 
than)2BSL 2 4 8 12 16 24 32 40 4816
TD/EOT52
EOS
Vital signs X X X X X X X X X X X X X
12-lead ECG4X X X
Liver Biopsy14X X Biopsy to be 
performed no later 
than 2 weeks prior 
randomization
Adverse Events  / Serious 
AEX X X X X X X X X X X X X

[COMPANY_001] Confidential Page 60
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Periods Screening Treatment Period Post 
Treatment 
Follow UpNotes
Week -10 
to    
-2-21
(no 
later 
than)2BSL 2 4 8 12 16 24 32 40 4816
TD/EOT52
EOS
Modified AUDIT 
questionnaire15X X X X X X X X X X X X
Randomization via IRT S
Contact [CONTACT_12067] X X X X X X X X X X X X
Drug dispensing S S S S S S S S
Drug administration record X X X X X X X X X
Drug compliance S S S S S S S S
AHA Diet Review S S S S S S S S S
Diet Compliance X X X X X
Exercise assessment S S S S S
Blood collection
Hepatitis serology5X
Liver tests X X X X X X X X X X X X X
Serum BUN and 
CreatinineX X X X X X X X X X X
Coagulation panel X X X X X X Only INR at screening 
visit 2

[COMPANY_001] Confidential Page 61
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Periods Screening Treatment Period Post 
Treatment 
Follow UpNotes
Week -10 
to    
-2-21
(no 
later 
than)2BSL 2 4 8 12 16 24 32 40 4816
TD/EOT52
EOS
Hematology X X X X X X X
Clinical chemistry  panel7X X X X X X X
HbA1c X

[COMPANY_001] Confidential Page 62
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Periods Screening Treatment Period Post 
Treatment 
Follow UpNotes
Week -10 
to    
-2-21
(no 
later 
than)2BSL 2 4 8 12 16 24 32 40 4816
TD/EOT52
EOS
Urine
Dipstick / routine 
Urinalysis with Reflex 
MicroX X X X X X X X X X X
Serum pregnanc y test12X
Urine pregnancy test12S S S S S S S S S S S S The urine pregnancy 
test should be 
performed every 4 
weeks up to the follow 
up visit, including at 
week 20, 28, 36 and 
44, and during any
treatment extension 
period.
Drug screen X X
Study Com pletion Form X

[COMPANY_001] Confidential Page 65
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.[ADDRESS_1048665] be notified within 2 days and thereason for not entering 
the study  will be recorded on the appropriate eCRF. In addition, the following eCRFs should 
be completed: Visit Date, Informed Consent, Demograph y, Inclusion/Exclusion Criteria, 
Subject Re-Screening (if applicable), Disposition, Withdrawal of Consent (if applicable) and 
AE should be completed for any SAEs that occurred during the screening epoch. Adverse events 
that are not SAEs will be followed by  [CONTACT_37255] y in the source data.
If a patient is a screening failure, but is rescreened and subsequentl y enrolled, the reason for the 
original screening failure must be documented in the source documents. A new subject ID will 
be assigned to the patient.  
If for any reason the patient is a screen failure, the patient may be rescreened. There is no 
restriction on the number of times a potential patient may  be rescreened or on how much time 
must pass from the date of screen failure and the date of rescreening.
If a patient rescreens for the study, THEN the patient must sign a new I CF and be issued a new 
patient number prior to any screening assessment being conducted for the patient under the new 
screening patient number. For all patients, the investigator/qualified site staff will record if the 
patient was rescreened on the rescreening eCRF and any applicable screening numbers the 
patient was issued prior to the current screening number.
The date of the new informed consent signature [CONTACT_765125]. Informed Consent for a rescreened patient 
must be obtained prior to performing any study -related assessment or collecting any data for 
the new Screening Visit. For rescreening, all screening assessments must be performed as per 
protocol.
Investiga tors will have the discretion to record abnormal test findings on the medical history 
eCRF whenever in their judgment, the test abnormality occurred prior to the informed consent 
signature. 
6.1.1 Pre-screening
Prior to screening visit 1 optional pre-screening assessments may be carried out, including 
 assessments and/or local laboratory  tests (HbA1c, platelets, INR, total bilirubin, ALT, 
AST, Alkaline phosphatase and serum albumin as applicable) to assess patient eligibility  for 
inclusion. Prior to any  assessments being carried out the pre -screening informed consent form 
must be signed b y the patient.
Only  data related to SAE’s causally  related tostudy procedures (i.e. blood sampling) will be 
reported . All other data related to pre-screening will be recorded only in the source 
documentation.

[COMPANY_001] Confidential Page 66
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.2 Patient demographics/other baseline characteristics
All baseline assessments should be performed prior to first study  treatment administration. 
These may be in the screening period (e.g. demographics) or at the Randomization Visit (e.g. 
PROs), depending on the assessment. 
6.2.1 Demographic Information
Patient demographic data to be collected at screening on all patients include: age, gender, race, 
ethnicity and child -bearing potential (for females only ).
6.2.2 Medical history
Any relevant medical history including surgical/medical procedures, protocol solicited medical 
history , and/or current medical conditions before obtaining informed consent will be recorded 
in the Medical History eCRF. Significant findings that are observe d after the patient has signed 
the informed consent form and that meet the definition of an AE must also be recorded in the 
AE eCRF (see Section 7.[ADDRESS_1048666] AEs during the screening period). 
Whenever possible, diagnoses and not sy mptoms will be recorded. 
Investigators will have the discretion to record abnormal test findings on the medical history 
eCRF whenever in their judgment, the test abnormality  occurred prior to the informed con
sent 
signature.
6.2.[ADDRESS_1048667] (AUDIT) will be administered to the patients at the screening visit 2 and as 
indicated inTable 6-1. At screening visit 2 the 10-item questionnaire will be used, whereas at 
the following visits, the shortened version (AUDIT- C), a 3 -item questionnaire will be used.
6.2.4 Smoking history
The current and/or previous use of tobacco products will be recorded, as well as the estimated 
number of pack -years based on the approximate consumption per year. Non-smokers will be 
advised not to start smoking during the stud y.
6.2.5 Prior and concomitant medications 
Concom itant medications and prior medications taken over the 6 months preceding study 
enrollment will be captured at the screening visit, and updated at the baseline visit. 
6.2.6 Liver evaluation 
[IP_ADDRESS] Liver biopsy 
Patients must have histologic evidence of NASH and liver fibrosis stage 2 or 3 (NASH clinical 
research network (CRN) staging criteria) demonstrated on liver biops y during the Screening 
period. Alternativel y, a historical biopsy  can be used if performed within 6 months prior to 
screening, if:

[COMPANY_001] Confidential Page 68
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.2.8 Screening visit 2 –additional assessments
The second screening visit should only be conducted if eligibility  is confirmed at screening visit 
1. Assessments for this visit include: Liver biopsy ,  
and other non
-lab assessments as indicated in Table 6-1.
The period between screening visit 1 and the anticipated randomization / baseline visit isa
maximum of [ADDRESS_1048668] (if applicable) . Both repeat 
tests should be in compliance with protocol requirements be fore randomization of the patient. 
6.[ADDRESS_1048669] udy personnel during the site monitoring visitsusing m edi cationpack numbers,
Drug Label Form information and information co llec tedby[CONTACT_12067].
6.4 Efficacy
All efficacy  assessments should be performed prior to the administration of study  treatment. 
The recommended order for the efficacy  assessments is described below. 
All remaining study  visits procedu res (e.g. laboratory  samples collection, vital signs 
measurement,  etc.) must be completed prior to administration of study  treatment. 

[COMPANY_001] Confidential Page 69
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.4.[ADDRESS_1048670], GGT, total alkaline phosphatase (and isoenzy mes if total alkaline phosphatase 
is >ULN, and 5’nucleotidase if either GGT or total alkaline phosphatase is > ULN during study 
participation), total bilirubin, direct bilirubin and albumin will be assessed as indicated in Table 
6-1.
If the total bilirubin concentration is increased above 1.[ADDRESS_1048671] reactive bilirubin will be quantified. The methods for assessment and recording are 
specified in the laboratory  manual. Some of the liver tests may be completed as part of the blood 
chemistry  panel.
6.4.3 Coagulation tests
Coagulation parameters including APTT, PT, INR and TT will be assessed as indicated inTable 
6-1.
The methods for assessment and recording are specified in the laboratory  manual.

[COMPANY_001] Confidential Page 70
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.4.[ADDRESS_1048672] paired liver biopsies (Baseline and EOT, after 48 weeks of treatment).  
Fibrosis staging and scores of steatohepatitis markers (steatosis,  
)  will be determined by a Central Reader. Five (5) toeight 
(8) unstained liver biopsy  sections, must be prepared and submitted to the central 
histopathologist who will confirm eligibility  prior to randomization.  If a suitable historical 
biopsy  sample from which slides can be prepared is not available, the liver biopsy  can be 
performed any time during the 10 week screening period, and should only be performed in 
subjects who fulfill Screening visit 1 inclusion criteria.   
  Additional details regarding liver biopsy  requirements can be found in 
the accompan ying central biopsy  manual. 

[COMPANY_001] Confidential Page 71
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.4.[ADDRESS_1048673] markers of NASH. 
Improvement in steatosis and fibrosis as determined by [CONTACT_765103] a 
valid endpoint by [CONTACT_765104] (Sany al et al 2016 ).
.
6.[ADDRESS_1048674] safet y parameters and measures will be collected including adverse events and serious 
adverse events according to definitions and process detailed in the protocol .
6.5.1 Physical examination 
A physical examination of the patient will be performed on patients according to the schedule 
defined in Table 6 -1.
A complete physical examination will include the examination of general appearance, hydration 
status, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, 
lymph nodes, extremities, vascular and neurological systems. If indicated based on medical 
history  and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be performed.
Information for physical examinations must be included in the source documentation at the 
study  site. Signi ficant findings that are present prior to signing the Informed Consent Form must 
be included in the Medical History  screen on the patient’s CRF. Significant findings that occur 
after signing the Informed Consent Form which meet the definition of an AE must be recorded 
in the Adverse Event screen of the patient’s CRF ( Section 7).

[COMPANY_001] Confidential Page 73
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
One sample of serum will be frozen and stored. This sample will be used to repeat study  lab 
tests when needed. It may  also be used for additional testing. 
[IP_ADDRESS] Hematology
Red blood cell (RBC) count, hemoglobin (Hb), hematocrit, mean corpuscular volume (MCV), 
white blood cell (WBC )count, absolute differential WBC count, and platelet count will be 
measured as indicated in Table 6-1.
[IP_ADDRESS] Clinical chemistry
The following will be measured as indicated in Table 6 -1:
Clinical chemistry :  sodium, potassium, chloride, bicarbonate, calcium, phosphate, blood urea 
nitrogen (BUN)/urea, serum creatinine, uric acid, creatine kinase, total protein,  
haptoglobin and HbA1c. The estimated glomerular filtration rate (eGFR) will be calculated 
using the MDRD formula based on the patient’s ageat the time of measurement, gender and 
race. 
At screening visit 1, the following assessments will be included: HbA1c, ferritin, transferrin 
saturation, iron, and if not historically  available also ANA, ASMA, and AMA.
Optional: If the investigator require s additional data to evaluate the current alcohol use of the 
patient at the screening visit, the carbohy drate deficient transferrin (CDT) test can be assessed 
using the central lab.
Liver tests: see Section 6.4.2
Coagulation: see Section 6.4.3
[IP_ADDRESS] Urinaly sis
A clean -catch midstream urine sample (approx. 
30 mL) will be obtained, in order to avoid 
contamination with epi[INVESTIGATOR_107183], and allow proper assessments, as indicated 
in Table 6-1.
Parameters to be evaluated by [CONTACT_765105] , pH, glucose, 
protein, bilirubin, ketones, nitrite, leukocy tes and blood. Standard microscopic evaluation of 
urinar y sediments will be performed if the urine dipstick test shows abnormalities.
Spot urine for calculation of protein to creatinine ratio can be aliquoted from the clean -catch 
urine specimen.
6.5.5 Electrocardiogram (ECG)
ECGs must be recorded after [ADDRESS_1048675], followed by [CONTACT_18651], and blood sampling. The Fridericia QT correction formula (QTcF) 
should be used for clinical decisions.

[COMPANY_001] Confidential Page 74
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Single [ADDRESS_1048676] be performed on the ECG machines provided for the study .
All ECGs will be independently  reviewed. Instructions for the collection and transmission of 
the ECGs to the independent reviewer will be provided in the ECG investigator manual.
12-lead ECG parameters (RR [Heart Rate], PR, QRS, and QT) are to be assessed.
Each ECG tracing must be label ed with study  number, subject initials, subject number, date and 
time, and filed in the study site source documents. 
In the event that a clinically  significant ECG abnormality  is identified at the site (e.g. severe 
arrhythmia, conduction abnormality  of QTcF > 500 ms), the ECG is repeated to confirm the 
diagnosis and 
both ECGs sent to the core laboratory for expedited review if applicable.
Clinically  significant abnormalities must be recorded on the relevant section of the appropriate 
CRFs capturing medical history /Current medical conditions/AE as appropriate.
6.5.[ADDRESS_1048677] at Screening Visit and/or Baseline Visit is an exclusion criterion for participating 
in the study . The urine pregnancy  test will be repeated every four weeks up to the follow up 
visit (see Table 6-1)including at week s 20, 28, 36,44 and during anytreatment extension period . 
The tests will be performed at the clinical center or at patient’s home . In case of home pregnancy 
test, the patients will be provided with urine pregnancy testkits. The result must be provided to 
the investigator at next scheduled visit, incase of positive test the patient must contact 
[CONTACT_765106] y. A positive urine pregnancy  test after start of study  drug requires 
immediate interruption of study  drug until serum hCG is performed and found to be negative. 
If positive, the patient will enter the post- treatment follow up period. See also Section 5.6.[ADDRESS_1048678] for this indication/patient population and have 
been used in previous trials in this indication or deemed appropriate based on non -clinical and 
early clinical experience. Patients are seen frequently during trea tment and will be assessed for 
safet y parameters
6.6 Other assessments
No additional tests will be performed on patients/subjects entered into this study .

[COMPANY_001] Confidential Page 75
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
6.6.1 Clinical Outcome A ssessments
[IP_ADDRESS] Patient Reported Outcomes (PRO)

[COMPANY_001] Confidential Page 76
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Trial feedback questionnaire
This trial will include an anon ymized questionnaire, ‘Trial Feedback Questionnaire’ for 
subjects to provide feedback on their clinical trial experience. Individual subject level responses 
will not be reviewed by [CONTACT_431]. Responses would be used by [CONTACT_456] ([COMPANY_001]) to 
understand where improvements can be made in the clinical trial process. This questionnaire 
does not collect data about the subject's disease, sy mptoms, treatment effect or adverse events 

[COMPANY_001] Confidential Page 77
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
and therefore would not be trial data. Should any spontaneous information be colle cted about 
AEs, this would be transferred to the safet y database.
6.6.2 Resource utilization
Not applicable.

[COMPANY_001] Confidential Page 78
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
7 Safety  monitoring
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [possibly  including abnormal laboratory  findings -see below], symptom or 
disease) in a subject or clinical investigation subject after providing written informed consent 
for participation in the study  until the end of study  visit. Therefore, an AE may or may not be 
temporally  or causally  associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse eve nt irrespective if a clinical event has occurred.

[COMPANY_001] Confidential Page 79
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
The occurrence of adverse events must be sought by [CONTACT_105] -directive questioning of the patient at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the patient durin g or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clin ical signs or sy mptoms, 
they are considered clinically significant, 
they require therapy . 
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_18532]. Investigators have the responsibility  for managing the safet y of individual 
patient and identify ing adverse event s. Alert ranges for laboratory  and other test abnormalities 
are included in Appendix [ADDRESS_1048679] be recorded in the appropriate CRF capturing AEs under the signs, 
symptoms or diagnosis associa ted with them, accompanied by  [CONTACT_6644]:
the 
severit y grade:
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents no rmal activities
its relationship to the study  treatment 
its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.
whether it constitutes a serious adverse event (SAE -See Section 7.2 for definition of 
SAE) and which ser iousness criteria have been met
action taken regard ing [investigational] treatment
its outcome (not recovered/not resolved; recovered/resolved; recovered/resolved with 
sequelae; fatal; or unknown)
All adverse events must be treated appropriately . Treatment may include one or more of the 
following: 
no action taken (e.g. further observation only ) 
[investigational] treatment interrupted/withdrawn
concomitant medication given 
non-drug therap y given 
patient hospi[INVESTIGATOR_057]/patient’s hospi[INVESTIGATOR_18533] (see Section 7.2 for definition of 
SAE)
Once an adverse event is detected, it must be followed until its resolution o r until it is judged to 
be permanent, and assessment must be made at each visit (or more frequently , if necessary ) of 

[COMPANY_001] Confidential Page 80
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
any changes in severity, the suspected relationship to the study drug, the interventions required 
to treat it, and the outcome.
Informatio n about common side effects alread y known about the investigational drug can be 
found in the Investigator ’sBrochure (IB). This information will be included in the patient 
informed consent and should be discussed with the patient during the study  as needed . Any new 
information regarding the safet y profile of the medicinal product that is identified between IB 
updates will be communicated as appropriate, for example, via an Investigator Notification or 
an Aggregate Safet y Finding. New information might requi re an update to the informed consent 
and has then to be discussed with the patient.
The investigator must also instruct each patient to report any new adverse event (beyond the 
protocol observation period) that the patient, or the patient’s personal physician, believes might 
reasonabl y be related to study  treatment. This information must be recorded in the investigator’s 
source documents; however, if the AE meets the criteria of an SAE, it must be reported to 
[COMPANY_001].
7.2 Serious adverse events
7.2.1 Definition of S AE 
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not asso ciated with any  
deterioration in condition
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling an y of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, e.g. defined as a n event that jeopardizes the patient or may  require 
medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (Annex IV ,ICH-E12D Guideline).

[COMPANY_001] Confidential Page 81
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_18534]. Examples of such events 
are intensive treatment in an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_121895] (Annex I V,ICH-E12D Guideline) .
Any suspected transmission via a medicinal product of an infectious agent is a lso considered a 
serious adverse reaction.
7.2.[ADDRESS_1048680] study  visitshould only be reported to 
[COMPANY_001] safet y if the investigator suspects a causal relationship to study treat ment. For patients 
who sign the pre-screening informed consent form, SAEs which occur after signature [CONTACT_765126] 
(i.e. blood sampling).
All follow -up information f or the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -
up to the original epi[INVESTIGATOR_30755] [ADDRESS_1048681] be reported separatel y as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sectio ns of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess the relationship of each SAE to each specific 
component of study  treatment, (if study  treatment consists of several components) complete the 
SAE Report Form in English, and submit the completed form within [ADDRESS_1048682] be reported as a follow -up to that event 
regardless of when it occurs. The follow -up information should describe whether the event has 
resolved or continues, if and how it was treated, whether the blind was broken or not, and 
whether the patient continued or withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert and 
is thought to be related to the study  treatment a Patient Safety  associate may urgently  require 
further information from the investigator for health authority  reporting. [COMPANY_001] may need to 
issue an Investigator Notification (IN) to inform all investigators involved in any study with the 
same stud y treatment that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant 

[COMPANY_001] Confidential Page 83
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Rule out acute viral hepatitis Ty pes A, B, C, D, and alcoholic hepatitis; hy poxic/ischemic 
hepatopath y; autoimmune hepatitis and biliary  tract disease
Obtain a history  o
f exposure to environmental chemical agents
These investigations can include serology  tests, liver biopsy , imaging and pathology 
assessments, hepatologist’s consultancy , based on investigator’s discretion. 
Any cases of possible drug-related liver injury  will be blindly  adjudicated by a hepatologist 
with expertise in drug-related liver injury  and as necessary  reviewed by [CONTACT_765107].
Subjects who permanently  discontinue study  drug due to potential liver toxicity  must be 
followed for close monitoring until abnormalities stabilize to baseline levels or baseline grade 
of abnormalit y and the subject is as ymptomatic. All follow -up information, and the procedures 
performed must be recorded on the appropriate CRFs.
7.[ADDRESS_1048683] to be considered during 
the course of the study :
Serum event:
confirmed (after ≥24h) increase in serum creatinine of ≥ 25% compared to baseline 
during normal hy dration status
Urine event
new onset ( ≥1+) proteinuria;
new onset ( ≥1+), hematuria or gl ycosuria 
Every  renal laboratory  trigger or renal event as defined in Table 15 -1in Appendix 3 should be 
followed up by [CONTACT_277336] 3 . 
7.5 Reporting of study  treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (E uropean Medicines Agency definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance wit h the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the appropriate CRF, irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being assoc iated with an AE/SAE.

[COMPANY_001] Confidential Page 84
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Table 7- 1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error 
typeDocument in CRF 
(Yes/No)Document in  eCRF 
capturing A EComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with an 
SAE
Misuse/Abuse Yes Yes, Yes, even if not 
associated with a SAE
7.[ADDRESS_1048684] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. 
The pregnancy  should be followed up to determine outcome, including spontaneous or 
voluntary  termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications.
Pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form and reported by [CONTACT_765108] y department. Pregnancy  follow -up should be 
recorded on the same form and should include an assessment of the possible relationship to the 
study  treatment. 
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the female partner.
8 Data revie w and database management 
8.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (eCRFs) with the 
investigators and their staff. During the study , [COMPANY_001] employ s several methods of ensurin g 
protocol and GCP compliance and the quality/integrit y of the sites’ data. The field monitor will 
visit the site to check the completeness ofpatient records, the accuracy  of data capture / data 
entry , the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, 
and to ensure that study  treatment is being stored, dispensed, and accounted for according to 
specificatio ns. Key study personnel must be available to assist the field monitor during these 
visits.  Continuous remote monitoring of each site’s data may be performed by a centralized 
[COMPANY_001] CRA organization. Additionally , a central analy tics organization may  analyze data & 
identify  risks & trends for site operational parameters, and provide reports to [COMPANY_001] Clinical 
Teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 

[COMPANY_001] Confidential Page 87
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
9 Data analy sis
Thefinal (end- of stud y) anal ysis will be conducted on all patient data collected up to the Week 
[ADDRESS_1048685] data at the time the trial ends. Any data analysis 
carried out independently by [CONTACT_765109].
9.1 Analysis sets 
Screened set (SCR) – All patients who signed the informed consent.
Randomized set (RAN) – All patients who received a randomization number, regardless of 
receiving trial medication.
Full analysis set (FAS) –All patients to whom study  treatment has been assigned*. 
Following the intent -to-treat (ITT) principle, patients are analyzed according to the 
treatment they  have been assigned to at randomization.
Safety  set (SAF) -All patients who received at least one dose of study  drug and have at least 
one post-baseline safet y assessment. Of note, the statement that a patient had no adverse 
events also constitutes a safety  assessment. Patients will be analy zed according to the 
treatment recei ved. 
*excluding patients who were mis-randomized and did not take investigational drug. Mis-
randomized patients are those who were not qualified for randomization, but were inadvertentl y 
randomized into the study .
The number of patients in each anal ysis set will be presented by [CONTACT_765110].
9.2 Patient demographics and other baseline characteristics
Demographic variables and other baseline characteristics will be summarized for the FAS. 
Descriptive statistics (mean, median, standard deviation, minimum and maximum) will be 
presented for continuous variables for each treatment group and for all patients (total). The 
number and percentage of patients in each category  will be presented fo r categorical variables 
for each treatment group and all patients (total). In addition, all relevant medical history , and 
protocol solicited medical history  will be summarized by  [CONTACT_1570].
9.3 Treatments
The duration of investigational treatment exposur e (days) will be summarized by [CONTACT_760624], both descriptivel y (i.e. mean, standard deviation, median, quartiles, 
minimum and maximum) and by [CONTACT_765111] (e.g. weeks).
The proportion of patients with dose reduction will be presented b y treatment group.
Medications will be identified using the WHO dictionary  including ATC code and presented 
for the SAF. Prior medications are defined as an y medications taken prior to the randomization 
visit (regardless of whether they are stopped or continued after randomization).  Concomitant 
medications and significant non-drug therapi[INVESTIGATOR_6544] -

[COMPANY_001] Confidential Page 88
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
blind period. Prior and concomitant medications will be summarized by [CONTACT_765112]. Medications will be presented in alphabetical order, by [CONTACT_765113] (the first level of the ATC code). Tables will also show the overall 
number and percentage of subjects receiving at least one drug of a particular ATC code and at 
least one drug in a particular anatomical main group.
Concomitant medications that were prohibited as per protocol and given during the conduct of 
the study  as well as significant non -drug therapi[INVESTIGATOR_765070].
9.4 Analysis of the primary  variable(s)
9.4.1 Primary  Variable(s)
Safety  (to be assessed in SAF):
Occurrence of adverse events
Occurrence of serious adverse events
Occurrence of adverse events resulting in permanent discontinuation
Occurrence of adverse events of special interest
Changes in Vital signs
Changes in Laboratory  data
9.4.[ADDRESS_1048686] Summary  table of absolute and relative 
frequency, overall and by [CONTACT_765114][INVESTIGATOR_765021] 
(risk definition for tropi[INVESTIGATOR_765071])
Changes in vital signs Descriptive statistics by [CONTACT_765115]
9.4.3 Handling of missing values/censoring/discontinuations
Imputation of incomplete adverse events start and end dates will follow standard conventions 
and will be described in detail in the statistical analy sis plan.

[COMPANY_001] Confidential Page 89
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
9.4.[ADDRESS_1048687] controlling for 
baseline fibrosis stage for each tropi[INVESTIGATOR_421736] + CVC 
combination vs. each monotherapy treatment, 
with supporting information from risk differences, 
odds ratios with 95% confidence intervals
Resolution of steatohepatitis (as determined b y 
central pathologist)Cochran -Mantel -Haenszel controlling for baseline 
fibrosis stage for each tropi[INVESTIGATOR_421736] + CVC 
combination vs. each monotherapy treatment, 
with supporting information from risk differences, 
odds ratios with 95% confidence intervals
There is a single secondary  objective in this study  which is to characterize the efficacy  of 
tropi[INVESTIGATOR_421736] + CVC in patients with NASH with fibrosis stage F2/F3 as assessed by  [CONTACT_765116] 48 weeks of treatment compared to monotherapi[INVESTIGATOR_014] (tropi[INVESTIGATOR_765072]) 
relative to baseline biopsy .  There are two estimands that will be used to evaluate this objective.
The first estimand is the difference on the proportion of patients on the different 
tropi[INVESTIGATOR_421736] +CVC regimens who achieve at least a one point improvement in fibrosis at Week 
[ADDRESS_1048688] 24 weeks (even if a Week 48 biopsy was obtained) will have their outcome imputed by 
[CONTACT_111012] (MI ). For subjects who remain on their randomized study  treatment for at 
least 24 weeks, but discontinue study  treatment prior to Week 48, available Week 48 biops y 
results will be used as observed.  This is a hy pothetical strategy  addressing the question “what 
would be the outcome if subjects had stayed at least 24 weeks on treatment and a Week 48 
biopsy  had been obtained”. Treatment differences between tropi[INVESTIGATOR_421736] +CVC combination 
therapy and monotherapy  with tropi[INVESTIGATOR_765073] a Cochran- Mantel -
Haenszel test controlling for baseline fibrosis stage (F2/F3). The estimand will be evaluated in 
the FAS population.  
The second estimand is the difference in the proportion of patients on the different 
tropi[INVESTIGATOR_421736] +CVC regimens who achieve resolution of steatohepatitis at Week [ADDRESS_1048689] their outcome imputed by [CONTACT_765117] (MI). 
The handling of intercurrent events (discontinuation of assigned treatment) is e quivalent to the 
first estimand as described above Treatment differences between tropi[INVESTIGATOR_421736] +CVC combination 
therap y and monotherapy  with tropi[INVESTIGATOR_765073] a Cochran- Mantel -

[COMPANY_001] Confidential Page 90
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Haenszel test controlling for baseline fibrosis stage (F2/ F3). The estimand will be evaluated in 
the FAS population. 
Due to COVID -19 pandemic, it may  not be possible for patients to return on time for Week 48
visit to perform liver biopsy and according to drug dispensing plan in Section 5.5.2 , the Week 
48liver biops ycan be delay ed by [CONTACT_3450]  10 weeks. Since the purpose of the secondar y 
efficacy  anal ysis is to evaluate the potential histological benefit of stud ytreatment , all biopsies 
obtained, including those from eligible patients after week 48 , will be included in the anal ysis. 
Sensitivity analyses :
Sensitivity  analyses will be conducted to account for delay ed Week 48 biopsies due to extended 
treatment under COVID -19 pandemic. Further details are to be described in the statistcal 
analysis plan (SAP).
9.5.2 Safety  variables
All safet y variables (i.e. adverse events, laboratory  data, vital signs, and ECG) will be 
summarized by [CONTACT_765118]. Safet y variables which are part of the 
primary  variables are listed in Table 9-1as well. Analy ses of the safety  variables will be 
performed in the Safet y Set.
[IP_ADDRESS] Adverse events
Treatment emergent adverse events (events started after the first dose of study  treatment or 
events present prior to the first dose of study  treatment but increased in severity  based on 
preferred term) will be summarized. AEs will be summarized by  [CONTACT_1601], for each treatment 
group, the n
umber and percentage of patients having experienced
Any adverse event (AE),
Any serious adverse event (SAE),
Any adverse event by  [CONTACT_64205] (SOC),
Any adverse event by  [CONTACT_11702],
Any adverse by  [CONTACT_926] ,
Any adverse event possibly  related to study  treatment (investigator assessment) ,
Any adverse event resulting in discontinuation of study  treatment ,
Any adverse events of special interest for tropi[INVESTIGATOR_765074] .
Exposure adjusted tabulations of adverse events and tabulations of appropriate adverse events 
according to defined intervals will be provided as well. If a patient reported more than one 
adverse event with the same preferred term, the adverse event with the greatest severit y will be 
presented. If a patient reported more than one adverse event within the same primary  system 
organ class, the patient will be counted only once with the greatest severity at the system organ 
class level, where applicable. A separate summary  will be provided for deaths, if they occur 
during the course of the study .

[COMPANY_001] Confidential Page 91
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
[IP_ADDRESS] Laboratory  data
The summary  of safet y laboratory  evaluations will be presented for the groups of laboratory 
tests (e.g. hematology , clinical chemistry ). Descriptive summary statistics for the change from 
baseline to each study  visit will be presented. These descriptive summaries will be presented 
by [CONTACT_109057], laboratory  test and treatment group. Change from baseline will only be 
summarized for patients with both baseline and post baseline values. Relative and absolut e 
frequencies of patients with liver events as defined in Appendix [ADDRESS_1048690] category  and t reatment group.
The number and percentage of patients with clinically  notable laboratory  results after baseline 
will be presented. Clinically  notable laboratory  results, for those parameters where ranges are 
available. Only patients with laboratory  results within the normal reference range from the 
central laboratory  at baseline will be included in the tabulations. 
Safety  laboratory  parameters which are also part of the efficacy  anal yses will be included in the 
safet y tables as well (e.g. liver enzymes, lipi[INVESTIGATOR_805]).
[IP_ADDRESS] Baseline definition
Generally ,  baseline  is  defined  as  the  last  assessment  before  date  and  time  of  first 
administration of study  drug; if only the date is available, the last assessment before or at the 
date of first administration of study drug will be used. For transaminases (ALT, AST, GGT )
and bilirubin, the baseline value will be calculated as the mean of the last two assessments 
before first administration of the study  drug, which are usuall y those taken at the Screening 2 
and Baseli ne visit (if a test was performed).
[IP_ADDRESS] Vital signs
Analy sis of the vital sign measurements using summary statistics for the change from baseline 
for each post-baseline visit will be performed. These descriptive summaries will be presented 
by [CONTACT_765119]. Change from baseline will only be summarized for patients 
with both baseline and post-baseline values. Patients with notable vital signs as defined in 
Appendix 1 will be listed.
[IP_ADDRESS] ECG
ECG data will be summarized by [CONTACT_10659] (post -baseline ECGs are performed at 
Week 24 and Week 48). 
The Fridericia QT correction formula (QTcF) will be used for clinical decisions and for analyses.
Notable QTcF values and changes from baseline w ill be summarized at Week 24 and Week 48. 
A notable value is defined as a QTcF interval of greater than 450 ms. The categories used for 
the change (increase) in QTcF are: ≤30 ms, > 30 to ≤60 ms and > 60 ms.

[COMPANY_001] Confidential Page 92
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
9.5.3 Resource utilization 
Data relating to resource utilization will be used for the purpose of economic evaluation which 
will be carried out and reported as a separate activity .

[COMPANY_001] Confidential Page 93
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J

[COMPANY_001] Confidential Page 94
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
9.[ADDRESS_1048691] to 
expected speed of enrollment and duration of the study , not on formal statistical criteria .
9.8.1 Power considerations with given sample size for safety  assessment
Events with a true incidence of 30% and above are likely to be observed (almost 100% 
probability ) in a group of 50 patients (size of each treatment group). Events with true incidences 
below 10% down to 3% are still ver y likel y to be observed, while events are observed with less 

[COMPANY_001] Confidential Page 95
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
than 50% probabilit y only if the true incidence is less than about 2.5% (Figure 9-1). It is 
noteworth y, however, that a single patient constitutes 2% in a sample of 50.
Figure 9
-1 Binomial probability  to observe an event with given sample size
Probabilities of theincidence being below a certain threshold are plotted in Figure 9-2for a 
sample size of 50 patients when the event is observed in 0, 1, 2, ...,10 patients (assuming a beta 
distribution with prior shape parameters 0.33, 0.33).

[COMPANY_001] Confidential Page 96
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Figure 9-2 Predictions for probability  of event based on observed number
For example, if 0 events are observed, the probability (Prob) that the incidence is ≤ 5% would 
be 98.7%. If an event is observed in one patient, the probability  that the incidence is ≤ 5% would 
be 86.6%. Similarly , if an event is observed in 10 patients (one fifth), the probability  that the 
incidence is ≤ 20% would be approximately  50% (calculated using R function pbeta).
9.8.2 Power considerations with given sample size for efficacy  assessment
To evaluate the effectiveness of tropi[INVESTIGATOR_421736] + CVC with respect to the proportion of pa tients 
who have at least a one point improvement in fibrosis at Week 48 compared to baseline (i .e, 
the response rate), one needs to consider the effect size that one is able to detect with respect 
to both tropi[INVESTIGATOR_765075] y.  
For CVC, based on information from the CENTAUR Phase 2b st udy, Friedman 2017 ), it 
can be assumed that the monotherap y response rate at Week 48  in F2/F3 patients would 
be approximately  35%
For tropi[INVESTIGATOR_421736], a response rate of 42% i s assumed  (best
-case scenario) based on the 
interpolation of expected Week 72 response rate and assuming linear improvement over 
time
For the combined effect of tropi[INVESTIGATOR_421736] + CVC it will be assumed that 75% of the efficacy  
for CVC will be added to the effe ct of tropi[INVESTIGATOR_421736] (i.e. a response rate of 69%)
For comparisons between tropi[INVESTIGATOR_421736] +CVC and CVC monotherapy a 2-group continuity  
corrected χ2test of proportions with type error 0.10 (2-sided, no adjustment for multiple 
comparisons), a sample size of 50 per group results in a power of 95% (nQuery  Advisor 7.0). 

[COMPANY_001] Confidential Page 97
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Forcomparisons between tropi[INVESTIGATOR_421736] +CVC and tropi[INVESTIGATOR_765076]  a 2-group contin uity 
corrected χ2test of proportions with type error 0.10 (2-sided, no adjustment for multiple 
comparisons), a sample size of 50 per group results in a power of 81% (nQuery  Advisor 7.0).
Further scenarios assuming different response rates for tropi[INVESTIGATOR_765077] 9 -4.
Table 9
-4 Power for detecting a treatment difference between tropi[INVESTIGATOR_421736] + CVC 
and tropi[INVESTIGATOR_765078] +
CVCPower
N =50/arm vs. 
tropi[INVESTIGATOR_765079] N =
50/arm vs. 
CVC 
monotherapy
Current target
42% response rate at 
Week 48 (50% 
improvement over 
OCA)½ effect of CVC added 
to tropi[INVESTIGATOR_421736] ((60%)48% 75%
¾ effect of CVC added 
to tropi[INVESTIGATOR_421736] (69%)81% 95%
Full effect of CVC 
added to tropi[INVESTIGATOR_421736] 
(77%)96% 99%
Response rate between 
target and OCA at 
Week 48 (35%)½ effect of CVC added 
to tropi[INVESTIGATOR_421736] (53%)48% 48%
¾ effect of CVC added 
to tropi[INVESTIGATOR_421736] (62%)81% 81%
Full effect of CVC 
added to tropi[INVESTIGATOR_421736] 
(70%)96% 96%
Worst case: tropi[INVESTIGATOR_765080] 
28% at Week 48½ effect of CVC added 
to tropi[INVESTIGATOR_421736] (46%)50% 23%
¾ effect of CVC added 
to tropi[INVESTIGATOR_421736] (55%)82% 56%
Full effect of CVC 
added to tropi[INVESTIGATOR_421736] 
(63%)96% 81%
*Power calculated assuming a two- sided T ype I error rate of 0.10
10 Ethical considerations
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese 

[COMPANY_001] Confidential Page 99
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
10.4 Publication of study  protocol and results 
The key design elements of this protoc ol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report the 
results of this trial will be either submitted for publication and/or posted in a publicly  accessibl e 
database of clinical trial results.
10.[ADDRESS_1048692] Quality  Management (QM) system that includes all activities 
involved in quality  assurance and qualit y control, including the assignment of roles and 
responsibilities, the reporting of results, and the documentation of actions and escalation of 
issues identified during the review of qualit y metrics, incidents, audits and inspections.
Audits of investigator sites, vendors, and [COMPANY_001] sy stems are perfor med by [CONTACT_105295], a group independent from those involved in 
conducting, monitoring or performing quality  control of the clinical trial. The clinical audit 
process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal Standard Operating Procedures (SOPs) , and are performed according to 
written [COMPANY_001] processes.
11 Protocol adherence
This protocol defines the stud y objectives, the study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safet y of patients/subjects should 
be administered as deemed necessary  on a case by [CONTACT_413]. Under no circumstances includin g 
incidental 
collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despi[INVESTIGATOR_105203], da ta, information, observation 
would be incidentally  collected, the investigator shall immediately  disclose it to [COMPANY_001] and 
not use it for any  purpose other than the study , except for the appropriate monitoring on study 
participants.
Investigators ascerta in they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_18686] B/IEC and health authorities, where required, it cannot be implemented. 
11.[ADDRESS_1048693] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an apparent immediate hazard 
to patients/subjects may be implemented immediately  provided the health authorities are 
subsequently  notified by [CONTACT_765120]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 

[COMPANY_001] Confidential Page 100
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section [ADDRESS_1048694]
Abdelmalek (2017) Favorable safet y and tolerability  of the dual CCR2/[ADDRESS_1048695] cenicriviroc 
in over 1000 subjects treated to date. Hepatology , 66(S1), 1177A.
Angulo P, Kleiner D, Dam- Larsen S, et al(2015). Liver Fibrosis, but No Other Histologic 
Features, Is Asso ciated With Long-term Outcomes of Patients With Nonalcoholic Fatty  Liver 
Disease. Gastroenterology, 149(2), 389 -397.e10.
Beste LA, Leipertz SL, Green PK, et al(2015). Trends in Burden of Cirrhosis and 
Hepatocellular Carcinoma by [CONTACT_765121], 2001–2013. 
Gastroenterology , 149(6), 1471
-1482.e5.
Burke LB, Kennedy  DL, Miskala PH et al (2008). The use of patient -reported outcome 
measures in the evaluation of medical products for regulatory  approval. Clin Pharmacol Ther; 
84:281 -283.
Calkin A, and Tontonoz P (2012). Transcriptional integration of metabolism by [CONTACT_497029] -activated receptors L XR and FXR. Nature Reviews Molecular Cell Biology, 13(4), 213 -
24.
Cariou B, and Cariou B (2008). The farnesoid X receptor (FXR) as a new target in non-alcoholic 
steatohepatitis. Diabetes & Metabolism, 34(6), 685-691.
Cella D, Hahn EA, Dineen K (2002) .Meaningful change in cancer - specific qualit y of life 
scores: Differences between improvement and worsening. Qual Life Res; 11(3):207 -221.
Cohen JC, Horton JD, & Hobbs HH. (2011). Human Fatty Liver Disease: Old Questions and 
New Insights. Science, 332(6037), 1519-1523.
Ekstedt M, Hasgtrom H, Nasr P, et al (2015) .Fibrosis Stage is the Strongest Predictor for 
Disease -Specific Mortality  in NAFLD After Up to 33 Years of Follow -Up. Hepatology ; 
61:1547-1554.
Flaishon L, Becker -Herman S, Hart G, et 
al (2004) .Expression of the chemokine receptor 
CCR2 on immature B cells negativel y regulates their cytoskeletal rearrangement and migration. 
Blood First Edit ion Paper, May  4, 2004; DOI 10.1182/blood-2003-11- 4013.
Foster T, Chalasani N, Harrison J, & Budoff M (2012). 935 Light Alcohol Consumption is 
Associated With Lower Prevalence of NAFLD: The Multi Ethnic Study  of Atherosclerosis 
(MESA). Gastroenterology , 142(5), S - 937
Friedman S, Ratziu V, Harrison S, et al (2017). A Randomized, Placebo- Controlled Trial of 
Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis. Hepatology
2018; 67:1754-1767 
Friedman S, Sany al A, Goodman Z, et al . (2016). Efficacy  and safet y study of cenicriviroc for 
the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR 
Phase 2b study  design. Contemporary  Clinical Trials, 47, 356
-365.

[COMPANY_001] Confidential Page 101
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Goodwin B, Jones S, Price R, et al (2000) . A Regulatory  Cascade of the Nuclear Receptors 
FXR, SHP -1, and LRH -1 Represses Bile Acid Biosy nthesis. Molecular Cell, 6(3), 517-526.
ICH Guideline E2D; Post-approval safet y data management: definitions and standards for 
expedited reporting (2004) .
Kabban y MN,Selvakumar P, Watt K,et al (2017). Prevalence of Nonalcoholic Steatohepatitis -
Associated Cirrhosis in the [LOCATION_002]: An Analy sis of National Health and Nutrition 
Examination Survey  Data. Am J Gastroenterol 2017; 112:581 –587.
Laffitte B, Vig P, Mueller P
,et al (2017) . LJN452/CVC combination therapy  shows additive 
effects on NAS vs. monotherapi[INVESTIGATOR_765081] . AASLD 2017, poster # P - 2052
Lefebvre E, Gottwald M, Lasseter K,et al (2016). Pharmacokinetics, Safet y, and CCR2/CCR5 
Antagonist Activity  of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. 
Clinical and Translational Science, 9(3), 139 -148.
Lefebvre E. (2014). Pharmacokinetics and safety  of multiple -dose cenicriviroc, a novel, oral, 
once -daily CCR2 and CCR5 antagonist, in adults with mild or moderate hepatic impairment. 
Hepatology , 60(6), 1275A.
Mossanen J, Krenkel O, Ergen C, et al (2016). Chemokine (C-C motif) receptor 2-positive 
monocy tes aggravate the early phase of acetaminophen
-induced acute liver injury . Hepatology , 
64(5), 1667-1682.
Mudaliar SHenry R, Sany alA, et al (2013). Efficacy  and Safet y of the Farnesoid X Receptor 
Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty  Liver 
Disease. Gastroenterology, 145(3), 574 -582.
Neuschwander -Tetri BA, Loomba R, Sany al AJ,et al (2015) .Farnesoid X nuclear receptor 
ligand obeticholic acid for non -cirrhotic, non -alcoholic steatohepatitis (FLINT): a multicentre, 
randomised, placebo -controlled trial. Lancet; 385(9972):956 -965.
Neuschwander -Tetri BA, & Neuschwander -Tetri B. (2003). Nonalcoholic steatohepatitis: 
Summary  of an AASLD Single Topic Conference. Hepatology , 37(5), 1202 -1219.
Patrick DL, Burke LB, Powers JH, et al (2007) .Patient -reported outcomes to support medical 
product labeli ng claims: FDA perspective. Value in Health; 10 (Suppl 2):S125- S137.
Pattni SS, Brydon WG, Dew T,et al (2012) .Fibroblast Growth Factor 19 and 7a-hydroxy-4-
cholesten-3- one in the diagnosis of patients with possible bile acid diarrhea. Clin Trans 
Gastroent erol; 3: e18.
Porez G, Prawitt G, Gross B, et al (2012). Bile acid receptors as targets for the treatment of 
dyslipi[INVESTIGATOR_765082]. Journal of L ipid Research, 53(9), 1723-1737.
PuengelT, Krenkel O, Mossanen J, et al (2016). The Dual Ccr2/Ccr5 Antagonist Cenicriviroc 
Ameliorates Steatohepatitis and Fibrosis in Vivo by  [CONTACT_765122] I njured Liver. Journal of Hepatology , 64(2), S160.
Ratziu. (2015). Novel therapi[INVESTIGATOR_110234]: What is on the horizon? Journal of Viral Hepatitis, 
22, 10.

[COMPANY_001] Confidential Page 103
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
13 Appendix 1: Clinically  notable laboratory  values and vital 
signs
The central laboratory  will flag laboratory  values falling outside of the normal ranges on the 
central laboratory  reports. Investigators are responsible for reviewing these abnormal values for 
clinical significance, signing the laboratory  reports to indicate their review, and reporting values 
considered clinically  significant inthe appropriate eCRF. Any clinicall y significant abnormal 
laboratory  value should be evaluated and followed-up by [CONTACT_6630] a cause 
for the abnormality  is determined.
SEE APPENDIX [ADDRESS_1048696] 
TRIGGER DEFINITIONS AND FOLLOW -UP REQUIREMENTS.
For ECGs, a notable QTc value is defined as a QTcF (Fridericia) interval of >450 msec for
males or > 460 msec for females, all such ECGs will be flagged by [CONTACT_765123].
For vital signs, please see Table 13-1 for notable abnormalities.
Table 13-1 Notable abnormalities in vital signs
Vital signs Notable abnormalities
Absolute Relative to baseline
Pulse rate (beats/min) > 130
< 40 > 120 and increase from baseline ≥ 15
≤ 50 and decrease from baseline ≥ 15
Blood pressure (mmHg) Systolic > 200
<75≥ 180 and increase from baseline ≥ 20
≤ 90 and decrease from baseline ≥ 20
Diastolic > 115
< 40≥ 105 and increase from baseline ≥ 15
≤ 50 and decrease from baseline ≥ 15
Note: these notable ranges should not be used as reference ranges to establish a clinical diagnosis

[COMPANY_001] Confidential Page 104
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
14 Appendix 2: Liver Monitoring and Follo w-up Requirements
For transam inases (ALT, AST, GGT) and bilirubin, the baseline value will be calculated as the mean of the last two assessments before fi rst 
administration of the study  drug, which are usually  those taken at the Screening [ADDRESS_1048697], or Bilirubin Elevations With or Without Liver Related 
Clinical Sy mptoms
Baseline Treatment -Emergent (Confirmeda)Liver -Related 
Clinical 
SymptomsbAction taken
MonitoringcStudy Drug
ALT and/or AST
Baseline ALT and/or AST 
< 2× ULNALT and/or AST 
> 3 × ULN but ≤ 5 × baselineNone Laboratory monitoring and causality 
evaluationContinue dosing
Present Comprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
ALT and/or AST
> 3 × UL N but ≤ 5 × baseline AND
total bilirubin > 2 × ULN 
(in Gilbert’s syndrome, see footnotef)With or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
ALT and/or AST 
> 3 × ULN and > 5 × baselineWith or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Permanently 
discontinue
Baseline ALT and/or AST 
≥ 2× ULNALT and/or AST 
> 2 × baseline but ≤ 3 × baselineNone Laboratory monitoring and causa lity 
evaluationContinue dosing
Present Comprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
ALT and/or AST 
> 2 × baseline but ≤ 3 × baseline AND
total bilirubin > 2 × ULNf Withor without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationdInterrupt dosinge

[COMPANY_001] Confidential Page 105
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Baseline Treatment -Emergent (Confirmeda)Liver -Related 
Clinical 
SymptomsbAction taken
MonitoringcStudy Drug
ALT and/or AST
> 3 × baseline With or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Permanently 
discontinue
Baseline normal or elevated 
ALT and/or AST valuesALT and/or AST
> 3 × ULN and > 2 ×baseline AND 
either
total bilirubin > 2 ×baseline OR
INR increase by >0.3 to a value >1.5With or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
ALP
Baseline ALP ≤ ULN ALP > 1.5 × ULN
(not due to known bone pathology)None Laboratory monitoring and causality 
evaluationcContinue dosing
Present Comprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
ALP > 1.5 × ULN 
(not due to known bone pathology) 
AND
total bilirubin > 2 ×ULNfWith or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
Baseline ALP > ULN ALP > 2 × baseline 
(not due to known bone pathology)None Laboratory monitoring and causality 
evaluationcContinue dosing
Present Comprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
ALP > 2 × baseline 
(not due to known bone pathology) 
AND
total bilirubin > 2 ×ULNfWith or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge

[COMPANY_001] Confidential Page 106
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Baseline Treatment -Emergent (Confirmeda)Liver -Related 
Clinical 
SymptomsbAction taken
MonitoringcStudy Drug
Total or Direct Bilirubin
Baseline total bilirubin ≤ 
ULNTotal bilirubin > 2 × ULNfWith or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
Baseline total bilirubin > 
ULNTotal bilirubin > 1.5×baselinefWith or without 
liver-related clinical 
sympto msComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationd, Interrupt dosinge
Baseline normal or elevated 
direct bilirubinDirect bilirubin > 1.5mg/dL With or without 
liver-related clinical 
symptomsComprehensive clinical evaluation and 
laboratory monitoring, as well as causality 
evaluationdInterrupt dosinge
ALT, AST, ALP and Total Bilirubin
Baseline normal or elevated 
valuesNormal or elevated values Present Laboratory monitoring and causality 
evaluationcContinue or 
Interrupt dosing 
as appropriateg

[COMPANY_001] Confidential Page 107
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
Baseline Treatment -Emergent (Confirmeda)Liver -Related 
Clinical 
SymptomsbAction taken
MonitoringcStudy Drug
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; eCRF = electronic case report f orm; INR = international normalized ratio; 
; ULN = upper limit of normal
aThe required confirmatory measurement should be obtained within 48 to 72 hours after the laboratory results become available. If prompt evaluation is not possible, study drug 
should be interrupt ed immediately (date of last study drug dose must be recorded in the eCRF).
bCombination of clinical symptoms of abdominal pain, worsening or new fatigue, anorexia, nausea, rash, vomiting, diarrhea, fever, pruritus, and/or eosinophilia (> 5%).
cFrequen t hepatic laboratory testing and clinical assessments, including a thorough causality evaluation, should be performed every o ther week at minimum, in consultation with 
the sponsor , until resolution of clinical symptoms and/or stabilization of liver biochem istries to baseline levels or baseline grade of abnormality. 
dThe sponsor should be notified of laboratory abnormalities and any clinical symptoms, and subjects should be closely monitored until reso lution of clinical 
symptoms/stabilization of liver bio chemistries to baseline levels or baseline grade of abnormality.
eStudy drug must be interrupted (date of last study drug dose must be recorded in the eCRF). The sponsor should be notified of laboratory abnormalities and any clinical 
symptoms, and subjec ts should be closely monitored until resolution of clinical symptoms/stabilization of liver biochemistries to baseline levels or baseline grade of abnormality. 
In subjects with elevations in liver biochemistry but who do not meet permanent drug discontinua tion criteria, study drug may be resumed if it is determined that complete 
resolution to normal or clinically comparable to baseline levels or baseline grade of abnormality (baseline value will be calculated as the mean of the last two assessments before 
first administration of the study drug, which are usually those taken at the screening 2 and baseline visit) has occurred and it is not considered that the deterioration in liver 
function was related to study drug. This must be documented based on biochemi cal parameters and clinical symptoms, per the discretion of the investigator and in consultation 
with the sponsor . Restarting study drug is only permitted following an interruption of less than 28 days ( see Section 5.5.5 ). If significant liver abnormalities recur at any time after 
restarting study drug, then study drug must be permanently discontinued.
fIn subjects with Gilbert’s syndrome, in place of the total  bilirubin criterion, use direct bilirubin > 2 × baseline.
gDevelopment of liver -related clinical symptoms in absence of biochemical abnormalities is an indication for prompt biochemical and physical evalua tion to decide whether 
continued dosing is appropriate. If prompt evaluation is n ot poss ble, study drug should be interrupted and subject followed for laboratory monitoring and causality evaluation.

[COMPANY_001] Confidential Page 108
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
15 Appendix 3: Specific Renal A lert Criteria and A ctions
Table 15-1 Specific Renal A lert Criteria and A ctions
Serum Event
Serum creatinine increase
25 –49% compared to baselineConfirm 25% increase after 24 -48h 
Follow up within 2 -5 days
Acute Kidney Injury: Serum creatinine increase 
50% compared to baselineFollow up within 24 -48h if possible
Consider study treatment interruption 
Consider patient hospi[INVESTIGATOR_059] /sp ecialized treatment
Urine Event
New dipstick proteinuria ≥1+
Albumin -or Protein -creatinine ratio increase ≥ 2-fold
Albumin -creatinine ratio (ACR) ≥ 30 mg/g or ≥3 
mg/mmol;
Protein -creatinine ratio (PCR )≥ 150 mg/g or > 15 
mg/mmolConfirm value after 24-48h
Perform urine microscopy
Consider study treatment interruption / or 
discontinuation 
New dipstick glycosuria ≥1+ not due to diabetes Blood glucose (fasting)
Perform serum creatinine, ACR 
New dipstick hematuria ≥1+ not due to trauma Urine sediment microscopy
Perform serum creatinine, ACR 
For all renal events:
Document contributing factors in the eCRF: co-medication, other co -morbid conditions, and additional 
diagnostic procedures performed 
Monitor patient regularly (frequency at investigator’s discretion) until either: 
Event resolution: sCr within 10% of baseline or protein -creatinine ratio within 50% of baseline, or
Event stabilization: sCr level with ± 10% variability over last 6 months o r protein -creatinine ratio stabilization at 
a new level with ± 50% variability over last 6 months.

[COMPANY_001] Confidential Page 109
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J

[COMPANY_001] Confidential Page 110
Amended Protocol Version 03 (Clean ) Protocol No. CLJC242A2201J
17 Appendix 5: The A merican Heart A ssociation (A HA) 
Recommended Diet
Optimization of diet can result in a marked triglyceride -lowering effect that ranges between 20% 
and 50%. Good practices include weight loss, reducing simple carbohy drates at the expense of 
increasing dietary  fiber, eliminating industrial- produced trans fatty acids , restricting fructose 
and saturated fatty acids, implementing a Mediterranean- style diet, and consuming marine -
derived omega -3 PUFA. 
AHA recommends the following:
Eat a variet y of fruit and vegetable servings every  day. Dark green, deep orange, or yellow fruits 
and vegetables are especially  nutritious. Examples include spi[INVESTIGATOR_87957], carrots, peaches, and berries. 
Eat a variety  of grain products every  day. Include whole -grain foods that have lots of fiber and 
nutrients. Examples of whole grains include oats, wh ole wheat bread, and brown rice. Eat fish 
at least [ADDRESS_1048698] for your heart. 
These fish include tuna, salmon, mackerel, lake trout, herring, and sardines. Stay at a healthy 
weight by [CONTACT_765124]. If you 
want to lose weight, increase your activity level to burn more calories than you eat. 
Eat foods low in saturated fat and cholesterol. Try to choose the following foods:
Lean meats and meat alternatives like beans or tofu
Fish, vegetables, beans, and nuts
Nonfat and low -fat dairy  products
Polyunsaturated or monounsaturated fats, like canola and olive oils, to replace saturated 
fats, such as butter 
Read food labels and limit the amount of Trans fat you eat. Trans fat is found in many  processed 
foods made with shortening or with partiall y hydrogenated or hydrogenated vegetable oils. 
These foods include cookies, crackers, chips, and many  snack foods. 
Limit sodium intake to less than 2,300 mg of sodium a day (about one teaspoon). Choose and 
prepare foods with little or no salt.  
Limit alcohol intake to 2 drinks a day  for men and 1 drink a day  for women. 
Limit drinks and foods with added sugar.
